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SUMMARY 
 
Human-microbial pathogen interaction is a constant battle between the two 
players whose aim is to overpower each other. During this interaction, a 
balance is maintained between the pathogen and the human host. However, 
opportunistic microbial pathogens start to overcome the human host when its 
physical and immune defenses get compromised. C. albicans is an 
opportunistic fungus which persists and causes muco-cutaneous and 
systemic infections in humans. C. albicans binds complement regulatory 
proteins Factor H, FHL-1, C4BP, and plasminogen which helps the fungus to 
inhibit further production of the opsonins C3b and iC3b, thereby evading the 
innate immune system. In addition, C. albicans binds to epithelial and 
endothelial cells to colonize and invade human tissues. Several secreted and 
cell surface proteins of C. albicans interact with complement proteins and 
adhere to host cells. However, homozygous deletions of the genes expressing 
the identified proteins do not totally abolish the interactions of C. albicans with 
the corresponding ligands, indicating that there are other C. albicans proteins 
which mediate the interactions. Moreover, mechanisms of the mentioned 
interactions are not fully understood. It is therefore the aim of this study to 
identify the roles of surface proteins of C. albicans and elucidate the 
mechanisms of their interaction with the cells and components of the human 
immune system.  
In this dissertation, two surface proteins of C. albicans are characterized with 
regards to their roles in the immune evasion and tissue invasion of the human 
host. Specifically, C. albicans phosphoglycerate mutase (Gpm1p) binds the 
host glycoprotein vitronectin which mediates the adherence of the fungus to 
endothelial cells and keratinocytes as demonstrated by adherence to HUVEC 
and HaCaT, respectively. gpm1 null mutant fails to adhere to endothelial cells 
whereas the Gpm1p-coated latex beads have increased adherence to 
endothelial cells as compared to BSA-coated latex beads used as control. 
These results indicate that Gpm1p mediates the adherence of C. albicans to 
endothelial cells. Furthermore, vitronectin is detected on the surface of 
HUVEC and HaCaT. Gpm1p colocalizes with the surface vitronectin of human 
cells illustrating that C. albicans Gpm1p adheres to human cells using 
vitronectin as ligand. A detailed investigation on the Gpm1p-vitronectin 
interaction revealed that Gpm1p binds vitronectin through its heparin binding 
sites and binding of Gpm1p to vitronectin is slightly affected by ionic 
conditions. 
The translation elongation factor-1 alpha (Tef1p), another cell surface protein 
of C. albicans, is demonstrated in this dissertation to mediate C. albicans 
interaction with human complement proteins. Tef1p binds to complement 
regulatory proteins Factor H and C4BP; and to C3 fragments C3b, C3d, C3dg 
and iC3b. Tef1p binds the plasma protein plasminogen. The Tef1p-bound 
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plasminogen is activated to plasmin in the presence of the tissue-type 
plasminogen activator and maintains degradation activity on the synthetic 
substrate S-2251, extracellular matrix proteins fibrinogen and vitronectin, and 
the opsonin C3b. Thus, Tef1p binds to plasminogen to degrade ECM proteins 
for tissue invasion and to degrade the opsonin C3b to avoid recognition by 
phagocytic cells. Moreover, it is demonstrated in this dissertation that the 
TEF1 gene is not essential in C. albicans as the tef1 null mutant has the same 
growth rate as the wild type in normal culture conditions. tef1 null mutant also 
grows normally as the wild type in the presence of osmotic and oxidative 
stressors, and cell-wall perturbing agents. These results are attributed to the 
presence of TEF2 gene which also encodes for the Tef1p protein. However, 
the tef1 null mutant is sensitive to the antimycotic drug hygromycin which 
directly inhibits the protein synthesis in C. albicans. tef1 null mutant also binds 
less C3d and plasminogen as compared to the wild type. Thus, deletion of 
TEF1 affects the binding properties of C. albicans to human complement 
proteins. Furthermore, Tef1p is involved in C. albicans-neutrophil interaction 
as the recombinant Tef1p binds to neutrophils and tef1 null mutant fails to 
elicit reactive oxygen species (ROS) production in neutrophils. 
Taken together, this dissertation demonstrates the importance of cell surface-
associated proteins of C. albicans in the virulence of the pathogen, may it be 
for evasion of the human immune system or adherence to host tissues. 
Elucidating the mechanisms on how C. albicans uses its surface proteins can 
give light to possible strategies on how to combat this menacing fungal 
pathogen which could eventually lead to improvement of the quality of human 
life. 
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ZUSAMMENFASSUNG 
 
Die Interaktion zwischen Mensch und Krankheitserreger ist ein 
immerwährender gegenseitiger Kampf mit dem Ziel, den jeweils anderen zu 
überwinden. Diese Interaktion resultiert in einem relativen Gleichgewicht 
zwischen Krankheitserreger und Wirt. Trotzdem sind opportunistische 
Krankheitserreger in der Lage, den Wirt zu besiegen, wenn dessen 
physikalische und Immunsystem-vermittelte Abwehr beeinträchtigt ist. C. 
albicans ist solch ein opportunistischer pilzlicher Krankheitserreger, welcher 
im Menschen persistiert und Schleimhaut- und systemische Infektionen 
auslösen kann. C. albicans bindet die Komplement-regulatorischen Proteine 
Faktor H, FHL-1, C4BP und Plasminogen. Diesen ist gemein, dass sie die 
Bildung der Opsonine C3b und iC3b inhibieren und somit eine Möglichkeit für 
den Pilz darstellen, die Mechanismen des angeborenen Immunsystem zu 
unterwandern. Außerdem bindet C. albicans an Proteine der Extrazellulären 
Matrix (ECM), welches die Kolonisierung und Invasion des menschlichen 
Wirtsgewebes erleichtert.  
Eine Vielzahl sekretierter und Zellwand-gebundener Proteine aus C. albicans 
wurden identifiziert, die an ECM-Bindung und Interaktion mit Komplement-
regulatorischen Proteinen teilnehmen. Durch Studien mit homozygoter 
Deletion der Gene, die für die entsprechenden Proteine kodieren, konnte 
gezeigt werden, dass dadurch die Fähigkeit von C. albicans an o.g. Liganden 
zu binden, nicht vollständig aufgehoben wird. Dies deutet darauf hin, dass C. 
albicans über weitere Proteine verfügen muss, die ebenfalls eine Interaktion 
vermitteln können. Zudem sind die genauen Interaktionsmechanismen für 
Bindung der genannten Liganden noch nicht vollständig verstanden. Daher ist 
das Ziel dieser Arbeit zum einen die Identifikation und Funktion weiterer 
Oberflächenproteine von C. albicans sowie zweitens die Aufklärung ihrer 
Interaktionsmechanismen mit Zellen des Menschen sowie den Proteinen des 
Immunsystems. 
In der vorliegenden Dissertation werden zwei Oberflächenproteine von C. 
albicans im Hinblick auf ihre Rolle bei der Immunevasion und der 
Gewebsinvasion im Detail untersucht. Die Phosphoglyceratemutase (Gpm1p) 
aus C. albicans  bindet das Wirtszell-Glykoprotein Vitronectin, was die 
Adhärenz des Pilzes an Endothelzellen und Keratinozyten vermittelt, 
beispielhaft gezeigt durch Adhärenz an HUVEC bzw. HaCaT. gpm1 
Deletionsmutanten sind nicht in der Lage, an Endothelzellen zu adhärieren, 
wohingegen Latex-Beads, welche mit Gpm1p beschichtet wurden, eine 
Bindung an Endothelzellen zeigen, was durch Verwendung von BSA-
beschichteten Latex-Beads als Negativkontrolle nicht der Fall war. Dies deutet 
darauf hin, dass Gpm1p in der Tat die Adhärenz von C. albicans an 
Endothelzellen vermitteln kann. Außerdem konnte Vitronectin direkt auf der 
Oberfläche von HUVEC und HaCaT nachgewiesen werden. 
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Folgeexperimente zeigen eine Kolokalisation von Gpm1p mit Vitronectin auf 
den humanen Zellen, was dafür spricht, dass C. albicans Gpm1p Vitronectin 
als Ligand für die Adhärenz verwendet. Detaillierte Studien der Interaktion 
zwischen Gpm1p und Vitronectin zeigen weiterhin, dass Gpm1p Vitronectin 
über die Heparin-Bindestellen bindet und die Stärke der Bindung durch 
ionische Bedingungen variierbar ist. 
Der Translations-Elongationsfaktor-1 α (Tef1p) stellt ein weiteres 
Zelloberflächenprotein von C. albicans dar. In dieser Arbeit konnte gezeigt 
werden, dass Tef1p die Interaktion von C. albicans mit Proteinen des 
menschlichen Komplementsystems vermittelt. Tef1p bindet die Komplement-
regulatorischen Proteine Faktor H und C4BP, sowie die C3 Spaltprodukte 
C3b, C3d, C3dg und iC3b. Außerdem bindet Tef1p an das Plasmaprotein 
Plasminogen. Gebunden an Tef1p, kann dieses in Anwesenheit des 
Gewebsspezifischen Plasminogenaktivators zu Plasmin aktiviert werden und 
behält seine Aktivität der Degradierung bei. Letztere wurde getestet durch 
Zugabe an verschiedenen Substraten, u.a. das synthetische Substrat S-2251, 
sowie an den ECM-Proteinen Fibrinogen und Vitronectin, bzw. am Opsonin 
C3b. Es kann gesagt werden, dass Tef1p Plasminogen bindet, um einerseits 
die Degradierung von ECM-Proteinen zum Zweck der Gewebsinvasion zu 
erleichtern und andererseits die Degradierung von C3b als Mechanismus der 
Immunevasion durch verhinderte Erkennung durch phagozytierende Zellen zu 
verwenden. Ferner wird gezeigt, dass das Gen TEF1 nicht essentiell für das 
Wachstum von C. albicans ist, da ein tef1-Deletionsstamm unter Standard-
Kulturbedingungen die gleiche Wachstumsrate wie der Wildtyp zeigt. Ebenso 
zeigt sich keine Unterschiede im Wachstum im Vergleich zum Wildtyp, wenn 
der tef1-Deletionsstamm der Gegenwart von osmotischen und oxidativen 
Stressoren und Zellwand-störenden Substanzen ausgesetzt ist. Diese Effekte 
sind zurückzuführen auf die Anwesenheit des TEF2-Gens, welches in C. 
albicans ebenfalls für das Tef1-Protein kodiert. Dennoch sind tef1-
Deletionsmutanten erhöht sensitiv gegenüber der antimykotischen Substanz 
Hygromycin, die direkt die Proteinsynthese in C. albicans inhibiert. tef1-
Deletionsmutanten binden im Vergleich zum Wildtyp weniger C3d und 
Plasminogen. Daher resultiert die Deletion von tef1 in einer geringeren 
Bindefähigkeit von C. albicans an Komplementproteine. Außerdem ist Tef1p 
an der Interaktion von C. albicans mit Neutrophilen beteiligt, da gezeigt wird, 
dass rekombinantes Tef1p an Neutrophile bindet und weiterhin tef1-
Deletionsmutanten eine mangelnde Fähigkeit zur Auslösung der Produktion 
von Reaktiven Sauerstoffspezies (ROS) in Neutrophilen aufweisen.  
Zusammenfassend kann festgehalten werden, dass mit dieser Arbeit die 
Bedeutung von Zelloberflächen-assoziierten Proteinen von C. albicans in der 
Virulenz, sei es für die Evasion des menschlichen Immunsystems oder die 
erleichterte Adhärenz an Zellen des Wirtes, gezeigt am Beispiel der Gpm1p 
und Tef1p, verdeutlicht wird. Die Aufklärung der Mechanismen, welche C. 
albicans in der Verwendung dieser Oberflächenproteine nutzt, kann 
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richtungsweisend für die Entwicklung neuer Strategien sein, mit denen dieser 
pathogene Pilz zukünftig noch besser bekämpft werden kann und dadurch die 
Lebensqualität der betroffenen Patienten verbessert werden kann.  
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 1 
1. INTRODUCTION 
 
Humans are surrounded by and exposed to a variety of microorganisms 
everyday. Microorganisms can be beneficial or harmful. Beneficial 
microorganisms living in the human body aid in efficient production and 
acquisition of nutrients from food. Other beneficial microorganisms help in 
warding off harmful microorganisms which cause diseases. Disease-causing 
(pathogenic) microorganisms have the ability to infect humans that can 
eventually lead to death. It is with this reason that the human body is in a 
constant state of battle with microbial pathogens. Mechanisms to balance 
each other out have been developed by both humans and microbial 
pathogens through million years of co-evolution. On the one hand, microbial 
pathogens try to infect and overpower the human host using secreted and 
cell-surface components; but on the other hand, the human host uses 
mechanisms involving the immune system to counteract the different 
strategies microbial pathogens use. It is these complex interactions between 
pathogenic microorganisms and human host that researchers all over the 
world are trying to elucidate to gain further knowledge on how to effectively 
inhibit pathogenic microorganisms which could eventually lead to elimination 
of diseases and to improve the quality of life. 
 
1.1. Human host 
 
1.1.1. Immune system 
The human immune system is composed of several physical, soluble and cell 
membrane-bound, and cellular components which make sure that the body is 
protected from foreign objects which can cause detrimental effects to the 
human body. The immune system’s first line of defense are the physical 
barriers provided by the skin, inner surfaces of the body, their secretions and 
associated normal microflora, and mechanical mechanisms which protect the 
body from entry of unwanted microorganisms. In terms of humoral and cellular 
protection, the human body relies on the innate and adaptive arms of the 
immune system. The innate immune system is classically defined as non-
specific response to foreign intruders of the human body. It mainly consists of 
the complement system, phagocytes (which include macrophages, 
neutrophils and dendritic cells), basophils and eosinophils, and natural killer 
(NK) cells . The complement system generates opsonins, anaphylatoxins and 
chemoattractants which induce the migration of phagocytes to the site of 
infection, inflammation, and formation of lytic pores. Adaptive immune system 
produces humoral and cellular specific responses to foreign objects present in 
the human body. Recently, it has been established that the innate immune 
system is closely related to the adaptive immune system through components 
of the complement system [1]. 
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1.1.1.1 The Complement System 
When the human body is intruded by foreign objects such as unwanted 
microorganisms, the first line of defense of the human immune system is the 
complement system. The complement system is a cascade of protein chain 
reactions which are composed of more than 40 soluble and cell surface-
associated proteins. The main functions of the complement system are to 
mark foreign objects (opsonization) inside the human body for elimination by 
phagocytes, to elicit an inflammatory response at the site of infection, and to 
lyze specific cell types.  
The complement system is activated by three different pathways. The first 
pathway is the spontaneous hydrolysis of C3 (alternative pathway, AP), the 
second pathway is induced by antibodies (classical pathway, CP), and the 
third is induced by mannose-binding lectins (MBL pathway). All of the three 
pathways converge to form the central complement molecule C3b. Figure 1 
shows the activation of the alternative pathway together with the components 
involved in the regulation and subsequent interaction with cells. CP and MBL 
pathway also produce the same cascade with a few differences.  
C4 and C2 are the main starting components involved in the initiation of CP 
and MBL pathway. In the CP, C4 is cleaved by the C1qrs complex which is 
produced when C1q binds to Antigen-Antibody (Ag-Ab) complexes resulting in 
the autocatalysis of C1r, which then cleaves C1s. The cleaved C1s 
enzymatically cleaves C4 into C4a and C4b. C4b binds C2, which becomes 
susceptible to C1s and is cleaved into C2a and C2b. C4b2a complex is 
formed which is known as CP C3 convertase which cleaves C3 into C3a and 
C3b. C3b binds to the activating surface to form C4b2a3b complex. C4b2a3b 
complex functions as C5 convertase, which cleaves C5 into C5a and C5b.  
In the MBL pathway, C4 and C2 activation can be achieved without antibody 
and C1 participation. The three proteins that initiate the MBL pathway are 
mannan-binding lectin/protein (MBL), and two mannan-binding lectin-
associated serine proteases (MASP and MASP2). MBL binds to certain 
mannose residues on activating surfaces and subsequently interacts with 
MASP and MASP2. The MBL-MASP-MASP2 complex is similar to Ab-C1qrs 
complex of CP and leads to activation of C4, C2 and C3. The rest follows as 
in CP. 
To avoid opsonization and lysis of normal human bystander cells near an area 
where complement is activated, the complement system employs several 
regulatory proteins which inhibit the deleterious action of the complement 
cascade. Complement regulatory proteins are either membrane-bound or 
soluble. The wide array of complement regulators act at the different stages of 
complement activation and activation pathways. Membrane-bound 
complement regulatory proteins include the complement receptors CR1 
(CD35), CR2 (CD21) and CR3 (CD18/CD11b), complement receptor of the Ig 
superfamily (CRIg), decay accelerating factor (DAF, CD55), membrane 
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cofactor protein (MCP, CD46), and protectin (CD59). Soluble complement 
regulatory proteins include Factor H, Factor H-like protein 1 (FHL-1), Factor 
H-related protein 1 (CFHR1), C4b-binding protein (C4BP), properdin, carobxy-
peptidase N, C1q C1INH clusterin, vitronectin, and plasminogen. Specific 
mode of action of these proteins are comprehensibly discussed in Zipfel et al. 
(2009) [3] Factor H of the alternative pathway and C4BP of the classical 
pathway act as cofactors for Factor I. With the help of the cofactors, Factor I 
inactivates C3b by degrading it into fragment components, thereby inhibiting 
the amplification loop which then inhibits further production of C3b. CFHR1, 
on the other hand, acts at the C5 level. By binding to C5, CFHR1 inhibits the 
conversion of C5 into the anaphylatoxin and chemoattractant C5a and the 
terminal complement complex component C5b [6] . 
Vitronectin is also a regulator of the terminal complement complex. Vitronectin 
binds to specific components of the complex (i.e., C7 and C9) which thereby 
blocks the formation of the pore complex [2,4]. Plasminogen has recently 
been found to regulate the complement system by binding to C3 and 
degrading the opsonin C3b [9].  
 
1.1.1.2. Neutrophils 
Neutrophils are a part of the family of white blood cells which are responsible 
for making sure that foreign objects are eliminated. Neutrophils mostly blocks 
the detrimental effects of pathogenic microorganisms by phagocytosis. 
Neutrophils kill pathogens by producing antimicrobial proteins, engulfing 
foreign cells, exposing them to low pH and production of reactive oxygen 
species (ROS), and production of neutrophil extracellular traps (NETs) [7].  
The activation of neutrophils has been comprehensibly discussed in detail by 
Amulic et al. (2011) [8]. The main points are as follows. Neutrophils are 
activated by the presence of components of foreign objects such as 
microorganisms. Cytokines such as tumor necrosis factor (TNF)-alpha, and 
interleukins IL-ß and IL-17 are produced when microbial components such as 
lipopolysaccharides (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP) 
are present. When cytokines and microbial components are present near the 
site of infection, endothelial cells express adhesion molecules such as P-
selectin, E-selectin and intercellular adhesion molecules (ICAMs). When 
these adhesion molecules on the luminal side of endothelial cells are sensed 
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Figure 1. The alternative pathway activation of the complement system. 
The alternative pathway is one of the three activation pathways of the complement system. It 
is activated by the spontaneous hydrolysis of the complement component C3 in the process 
called “tickover” producing C3(H2O). Binding of Factor B to C3(H2O) with subsequent 
cleavage to Bb by Factor D produces the C3 convertase. C3 convertase cleaves C3 into C3b 
and C3a. C3b participates in further production of more C3b by continuous binding of Bb to 
C3b producing the C3bBb convertase in the process called the “amplification loop”. C3b binds 
to activating surfaces and acts as ligand for different receptors on human phagocytes such as 
Complement Receptor 1 (CR1) and Complement Receptor of the Immunoglobulin 
superfamily (CRIg) for subsequent phagocytosis. Meanwhile, C3bBb is further used to form 
the C5 convertase (C3bBb3b) which cleaves C5 into C5b and C5a. C5a and C3a act as 
anaphylatoxins and ligands for C5a receptor (C5aR) and C3a receptor (C3aR), respectively, 
which produces inflammation, leucocyte migration and cytokine production. C5b binds C6, 
C7, C8 and C9 producing the terminal complement complex which forms pores on activating 
cell surfaces leading to lysis. The complement cascade is tightly controlled by several soluble 
and membrane-bound regulators. Soluble Factor H acts as co-factor for Factor I which 
degrades C3b to iC3b and further degradation of iC3b produces the C3d fragment. Factor H 
also binds to C3b to inhibit the convertase activity leading to its decay. Membrane-bound CR1 
and CRIg also act as inhibitors of the C3 convertase together with Decay Accelerating Factor 
(DAF) and Membrane Cofactor Protein (MCP). In addition Complement Factor H-related 
Protein 1 (CFHR1) inhibits the C5 convertase and the formation of the terminal complement 
complex (TCC). Vitronectin, clusterin and protectin are also inhibitors of the TCC formation. 
Inactive C3b (iC3b), when bound to activating surfaces, can also be recognized by other 
phagocyte membrane-bound complement receptors such as Complement Receptor 3 (CR3) 
and CRIg also leading to phagocytosis. Moreover, when the IgG coreceptor Complement 
Receptor 2 (CR2) on the surface of B cells recognize C3d, the threshold of B cell activation is 
lowered.  
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by the neutrophils, they express receptors on their surface, such as P-selectin 
glycoprotein ligand-1 (PSGL-1) and L-selectin which allow them to “roll” and 
subsequently have a firm attachment on the endothelial cell surface by 
expressing ß2 integrins. The engagement of ß2 integrins with ICAMs initiates 
the change in neutrophils which include cell spreading and beginning of the 
oxidative burst process. The course of endothelial barrier traversion happens 
until the neutrophils reach the site of infection by following a chemoattractant 
gradient. Upon interaction of chemoattractants and other pathogen-associated 
molecular patterns (PAMPs) to their respective receptors on the surface of the 
neutrophils, a signalling cascade starts which mostly involve the MAPK/ERK 
pathway leading to engulfment, formation of phagolysosome, lowering of pH, 
production of reactive oxygen species, degranulation involving release of 
antimicrobials such as defensins, and/or formation of neutrophil extracellular 
traps (NETs).  
Some of the well-studied neutrophil receptors are the complement and fMLP 
receptors, ß2 integrins and CD16 (FcγIII receptor). Complement receptors  
(such as CR3) recognize iC3b-opsonized cells or debris. ß2 integrins 
recognize intercellular adhesion molecule 1 (ICAM-1). Other neutrophil 
receptors include the Toll-like receptors (TLRs). TLR4 recognizes LPS, while 
TLR2 recognizes bacterial lipopeptides. TLR5 and TLR9 bind flagellin and 
DNA, respectively.  
Upon activation, neutrophils undergo respiratory burst where reactive oxygen 
species (ROS) are produced. ROS can modify and damage other molecules, 
making them effective microbial-killing substances. The ROS cascade begins 
when the NADPH oxidase complex assembles on the phagosomal and 
plasma membranes. When this happens, the molecular oxygen is reduced to 
superoxide. Superoxide can undergo several reactions producing different 
products. Rapid dismutation of superoxide leads to the formation of hydrogen 
peroxide while reaction of superoxide with nitric oxide forms the strong 
oxidant peroxynitrite. When myeloperoxidase (MPO) is released into the 
phagosome during degranulation, MPO can react with hydrogen peroxide to 
produce various reactive species, including hypochlorous acid. Hypochlorous 
acid is more reactive than superoxide which is thought to give it the capability 
to have direct antimicrobial effects in the phagosome.  
 
1.1.2.  Vitronectin 
Vitronectin is a human soluble and membrane-bound glycoprotein of humans. 
It appears as 75- and 65-/10-kDa protein found in the plasma at a 
concentration of 200-400 μg/ml. Vitronectin is produced mainly by the liver 
and is distributed to different organs through the blood. Vitronectin functions in 
the regulation of the complement system by inhibition of the terminal 
complement complex (TCC), cell adhesion, proliferation, cellular transport and 
an integral component of the extracellular matrix [10,11].  
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The structure of vitronectin is composed of the somatomedin-B (SMB) domain 
at the amino-terminus, followed by the Arg-Gly-Asp (RGD) motif, adjacent 
acidic epitope for high molecular weight kininogen binding, long connecting 
segment containing the collagen-binding domain, and the two hemopexin-like 
domains at the carboxy-terminus. The SBM domain contains the overlapping 
plasminogen activator inhibitor-1 (PAI-1) and the urokinase plasminogen 
activator/urokinase plasminogen activator receptor (uPA/uPAR) interaction 
sites. The RGD motif located directly adjacent to the SMB domain is 
responsible for the adherence to integrins on the human cell surface. The first 
hemopexin-like domain serves as specific binding site for infectious group A 
streptococci. The second hemopexin-like domain contains the basic heparin-
binding site composed of two heparin-binding consensus sequences which 
serves as the primary, conformation-dependent, binding site of vitronectin for 
heparin and other glycosaminoglycans [12,13]. 
 
1.1.3.  Plasminogen 
Plasminogen is a 92-kDa single chain human plasma glycoprotein that 
circulates in plasma as an inactive proenzyme at a concentration of ca. 2 μM. 
Plasminogen is primary synthesized and secreted by liver cells. Plasmin as 
the key enzyme of the coagulation system dissolves preformed fibrin clots and 
regulates fibrinolysis and homeostasis [14,16]. Furthermore, plasmin also 
degrades components of the extracellular matrix and the basal membrane, 
including laminin, fibrin, and fibrinogen [15,17]. Another function of plasmin is 
the activation of matrix metalloproteases and elastase, which regulate wound 
healing, tissue remodeling, tumor metastasis, and angiogenesis [15,16]. 
Plasminogen is composed of an N-terminal preactivation peptide (ca. 8 kDa), 
five consecutive disulfide-bonded kringle domains (K1–K5), and a serine 
protease domain at the C-terminus. During activation, plasminogen is cleaved 
at specific sites to release the protease plasmin. Plasminogen is a precursor 
of the protease plasmin. In humans, plasminogen is activated and converted 
to plasmin by urokinase-type plasminogen activator and tissue-type 
plasminogen activator. It can also be activated by activators of bacterial origin 
such as staphylokinase from Staphylococcus aureus and streptokinase from 
Streptococcus pneumoniae [17]. Once activated, the serine protease 
degrades various substrates such as fibrinogen, proteins of the extracellular 
matrix [9,15], immunoglobulin G (IgG) [18], and complement component C3 
[9,19].  
 
 
 
 
 
 
Introduction 
 7 
1.2. Microbial pathogens 
 
1.2.1. Candida albicans 
Among pathogenic microorganisms, fungi are known to cause major human 
infections worldwide. An important pathogenic fungus which causes invasive 
fungal infections is Candida albicans [20,22]. C. albicans is a diploid fungus 
which belongs to the family Ascomycota. It is a commensal microorganism 
which lives in the gut, oral-pharyngeal, vulvo-vaginal areas, and on skin of 
humans. However, C. albicans persists, colonizes, and causes infection when 
the human host has an impaired immune system either because of having an 
acquired immunodeficiency syndrome, or receiving immunosuppressive drugs 
because of transplantation or chemotherapy. In addition, C. albicans also 
turns into a pathogen when human normal microflora becomes imbalanced 
and when the integrity of epithelial cells gets compromised [21]. 
As a pathogen, C. albicans causes both systemic and mucocutaneous 
infections in humans. C. albicans possesses several traits which enhance 
pathogenicity of the fungus. This includes the ability to evade the immune 
system, switch from yeast form to hyphae form, secrete proteases, and 
express adhesins and invasins. The morphotype switching is a well-known 
trait of C. albicans which gives it the ability to invade and exert pressure in 
destroying human cells when inside [22,25,26]. C. albicans is known to 
secrete proteases to degrade specific human host components to aid in the 
invasion and establishment of infection [23,24]. Adhesins and invasins, either 
secreted or cell wall-bound, mediate attachment and invasion of host cells 
[25,26]. Proteins are either expressed on the surface or secreted to give C. 
albicans the advantage of binding to complement regulatory proteins for 
immune evasion [27,29]. 
 
1.2.1.1. Candida albicans cell wall 
C. albicans interacts with human host cells and soluble factors mainly through 
components of its cell surface. The cell wall architecture of C. albicans 
consists of two main layers. The outer layer is composed of mannans and 
glycoproteins while the inner layer contains chitin and ß-1,3 glucan. The inner 
and outer layers are linked by the ß-1,6 glucan. Mannans are found at the 
outer layer which are normally attached to proteins (mannoproteins). Also 
attached to the ß-glucans are proteins which are either covalently or non-
covalently bound. Glycophosphatidylinositol (GPI)-anchored proteins are 
attached to ß-1,6 glucan while Pir (proteins with internal repeats) proteins are 
directly attached to ß-1,3 glucan [28,30]. Non-covalently bound cell wall 
proteins are heterogeneously distributed on the cell surface. They may or may 
not be secreted, and they can be cell surface associated [29,31,32].  
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Figure 2. Cell wall components of C. albicans 
The architecture of C. albicans cell wall is divided into two: inner and outer cell walls. The 
inner cell wall contains chitin and ß-1,3 glucan. The outer cell wall is mainly composed of 
mannan and proteins. The outer and inner cell walls are connected by the ß-1,6 glucan. The 
glucan components are also bound by cell wall proteins through covalent and non-covalent 
bonds. 
 
 
Some proteins which are found on the C. albicans surface are non-
conventional [30,33]. Non-conventional or “moonlighting” proteins play other 
roles aside from their main identified functions. Most of the non-conventional 
cell wall-associated proteins have major functions intracellularly. They do not 
have secretion signal peptides but are detected extracellularly either as 
secreted or surface-bound. Their functions range from attachment to human 
cells via the extracellular matrix proteins to binding of soluble human proteins 
[31,32].  
Cell surface proteins which mediate C. albicans adhesion and invasion of host 
cells are called adhesins and invasins, respectively. Among the well-known 
adhesins and invasins, Als3  and Ssa1  are well-characterized. Als3 binds to 
the E- and N-cadherin on epithelial and endothelial cells, respectively [29,33]. 
Ssa1 is an additional cadherin ligand which C. albicans uses to invade human 
host cells [34]. Cell surface-associated proteins of C. albicans do not only bind 
host surface proteins but also soluble serum proteins. C. albicans binds 
serum proteins also for adhesion and invasion of human cells [29,37] . Among 
the moonlighting proteins, enolase is the well studied. It binds plasminogen 
and aids C. albicans to cross the blood-brain barrier in mice [38]. 
 
1.2.1.4. Candida albicans and the complement system 
During systemic candidiasis, C. albicans is exposed to components of the 
human blood wherein soluble components of the immune system are present. 
Upon contact with the blood, C. albicans activates the human complement 
system [39,42]. Candida albicans activates the human complement system 
through the three complement activation pathways. Besides the normal 
complement system activation via the classical pathway through binding of 
anti-Candida antibodies and subsequent recognition by C1q, C. albicans 
mainly activates the complement system by the alternative pathway 
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[40,41,43]. Normally, intact blastoconidia of C. albicans is resistant to 
alternative pathway activation. However, ß-glucans on the surface of C. 
albicans trigger the alternative pathway when mannan present on the outer 
layer of the cell wall becomes disrupted or blocked by anti-mannan 
antibodies, exposing the underlying glucans [42,44,45]. Specifically, ß-1,6 
glucan on the fungal cell surface triggers complement activation [43,46]. C. 
albicans also activates complement through mannose-binding lectin (MBL) 
pathway. The MBL pathway is important in opsonophagocytosis of yeast cells 
during hematogenous candidiasis as evidenced by the decreased C3 
deposition on C. albicans and reduced phagocytosis by neutrophils in MBL-
deficient sera [44].  
Activation of the complement system leads to the generation of the opsonin 
C3b. Further action of the complement cascade produces C3b fragments 
iC3b and C3d [46]. Candida albicans binds these C3b fragments through 
components present on the fungal cell surface [47,50-52]. Most of the C3d 
and iC3b receptors on the surface of C. albicans were identified using 
antibodies against the human complement receptors CR2 [48,49,53] and CR3 
[43,50-52], respectively. Candida Int1p binds iC3b [53-54] while several C. 
albicans surface proteins were isolated as C3d receptors based on their CR3-
like characteristics. ß-1,6 glucan also binds C3b/C3d [43]. 
Importance of the complement system during C. albicans infection was 
recently shown in that activated complement augments C. albicans-induced 
host cytokine production via C5a-C5aR signalling. Production of C5a 
augments production of pro-inflammatory cytokines IL-6 and IL-1ß but 
intracellular killing and phagocytosis are not affected [55]. In addition, the use 
of next-generation computational genetic analysis identified variations in C1q, 
C1r, C1s and their interaction with C5 to be relevant in the survival of murine 
model during C. albicans infection, underscoring the role of the early 
complement classical pathway activation components in the resistance to 
fungal infection [56]. 
Aside from C5a, C3a also exerts antimicrobial effects against C. albicans. 
C3a binds to C. albicans cell surface and induces membrane perturbations 
and release of extracellular material. C. albicans isolates were found to induce 
complement degradation, leading to generation of C3a [57] . 
Complement regulatory proteins also bind C. albicans to enhance 
antimicrobial activity of neutrophils. Members of the Complement Factor H 
family proteins (CFH, CFH-like protein-1, CFH-related protein-1 and CFH-
related protein-4) bind to C. albicans. CFH, CFHL-1 and CFHR1 increase 
attachment of neutrophils to C. albicans. Yeast-bound CFH and CFHR1 
enhance generation of reactive oxygen species and release of antimicrobial 
protease lactoferrin by neutrophils [58].  
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1.2.1.5. Immune evasion of C. albicans 
Pathogenic fungi such as Candida albicans and Aspergillus fumigatus are 
also known to bind regulatory proteins of the complement system to protect 
themselves from being recognized and opsonized by the effector cells of the 
innate immune system [35,36,59-61]. Regulatory proteins of the different 
pathways of the complement system are bound by fungal pathogens to inhibit 
further progress of the complement cascade. C. albicans takes advantage of 
the use of the complement regulatory proteins for its benefit to evade the 
complement system by binding several of these proteins. The complement 
inhibitors Factor H, FHL-1, CFHR1, and C4b-binding protein are bound by C. 
albicans which allow the fungus to inhibit the C3 conversion to the opsonin 
C3b, and stop the amplification loop which is responsible for the production of 
more C3b. Binding the terminal complement pathway inhibitor Factor H-
related protein 1 by C. albicans can lead to the inhibition of the production of 
the anaphylatoxin and chemoattractant C5a, which may allow the fungus to 
avoid attack by phagocytes [62]. 
So far, four surface proteins of C. albicans have been identified to bind 
complement regulatory proteins of the complement system. Phosphoglycerate 
mutase (Gpm1p) [61], pH-regulated antigen 1 (Pra1) [62], high-affinity glucose 
transporter 1 (Hgt1p) [63] and recently, glycerol-3-phosphate dehydrogenase 
2 (Gpd2) [65]. All of these proteins bind Factor H and the bound Factor H is 
active in acting as the cofactor of Factor I in C3b degradation which can lead 
to the inhibition of C3b deposition on the fungus, thereby inhibiting further 
recognition by phagocytes such as macrophages and neutrophils. Gpm1p and 
Pra1 bind to the short consensus repeats (SCRs) 6-7 and 19-20 of the Factor 
H molecule [61,62]. Among the four aforementioned proteins, Pra1 and Hgt1p 
also bind C4BP which inhibits the production of C3b from the classical 
pathway of complement activation [63,64]. Pra1 binds to the C4BP 
complement control protein domains 4, 7, and 8. In addition, Pra1 binds C3 to 
directly inhibit the activation of the complement cascade [66]. By directly 
binding to C3, Pra1 can inhibit the complement cascade leading to inhibition 
of production of the anaphylatoxins and chemoattractants C3a and C5a 
(Figure 3). 
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Figure 3. Complement evasion strategies of C. albicans.  
C. albicans expresses Gpm1p and Pra1 to evade the human complement system. Surface 
Gpm1p and Pra1 bind the alternative pathway complement regulators Factor H and FHL-1 
which act as cofactors for Factor I in inactivating the opsonin C3b producing iC3b. Pra1 binds 
the classical pathway regulator C4BP which also acts as cofactor for Factor I in converting 
C4b to iC4b. Inactivation of C3b and C4b leads to the inhibition of the C3 convertase. In 
addition, C. albicans secretes Pra1 which binds C3 to inhibit the production of C3b and the 
anaphylatoxins C3a and C5a.  
 
 
Aside from binding complement regulatory proteins for immune evasion, C. 
albicans secretes proteases Saps 4-6 which interfere and inactivate host 
complement components C3b, C4b and C5. The secreted proteases also 
inhibit the terminal complement complex (TCC) formation. Secretion of 
complement degrading proteases provides a highly efficient complement 
defense response of this human pathogenic yeast that acts after the 
immediate acquisition of host complement regulators to the cell surface [23]. 
Secreted aspartic proteases also have a role in degrading the antimicrobial 
peptide Histatin-5. In doing so, C. albicans can persist in the oropharyngeal 
area and cause infection [24].  
 
1.2.1.6. Candida albicans and vitronectin 
Clinical isolates of C. albicans bind to vitronectin. C. albicans binding of 
vitronectin is optimized when the fungus is grown at 37°C and optimal binding 
is at pH 4 [67]. C. albicans-vitronectin binding is significantly inhibited by 
heparin, suggesting that the glycosaminoglycan-binding region of vitronectin 
is involved in the interaction [68]. Heat and protease treatments on C. 
albicans decrease the vitronectin binding capacity of the fungus indicating that 
the vitronectin receptor on the surface of C. albicans is a protein [67]. 
A 30-kDa molecule of C. albicans was identified to bind to vitronectin based 
on SDS and ligand blotting by radiolabelled vitronectin [68]. Other studies 
showed that both yeast cells and germ tubes of C. albicans have human 
integrin-like receptors which specifically bind vitronectin. C. albicans in the 

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yeast phase expresses vitronectin receptors which are antigenically related to 
the vertebrate αvβ3 and αvβ5 integrins with molecular masses of  130, 110, 
100, and 84 kDa [69-71]. C. albicans germ tubes have vitronectin receptors 
which are  antigenically related to human αv, β3 and αvβ3, but not to αvβ5 [70].  
The C. albicans-vitronectin interaction is believed to be an important aspect of 
both C. albicans virulence and human host protection of itself against fungal 
infection. On one hand, C. albicans binding to vitronectin increases the 
fungus’ adherence to endothelial cells which could help in the dissemination 
of fungal cells during hematogenous infection or candidiasis and invasion of 
tissues during muco-cutaneous infection [69-71]. On the other hand, 
vitronectin increases the attachment of C. albicans to macrophages which 
could help in a more effective phagocytosis of the fungal cells [68]. 
 
1.2.1.7. C. albicans and plasminogen 
C. albicans binds plasminogen and bound plasminogen is activated to 
plasmin by human uPA or tPA as the fungus does not produce any 
plasminogen activators. Plasmin, when bound to C. albicans degrades 
fibrinogen [37]. At present, there are 11 C. albicans surface proteins which 
bind plasminogen as listed in Table 1. The binding of the enumerated C. 
albicans surface proteins to plasminogen involve lysine residues. 
 
Table 1. Plasminogen-binding surface proteins of C. albicans 
Name Reference 
Phosphoglycerate mutase (Gpm1p) [37,61] 
pH-regulated antigen 1 (Pra1) [37,62] 
Translation elongation factor 1 (Tef1p) [37] 
Catalase [37] 
Thioredoxin peroxidase [37] 
Alcohol dehydrogenase (Adh1) [37] 
Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) 
[37] 
Phosphoglycerate kinase (Pgk1) [37] 
Fructose bisphosphate aldolase (Fba1) [37] 
Enolase (Eno1) [38] 
glycerol-2-phosphate dehydrogenase (Gpd2) [65] 
 
1.2.1.2. Candida albicans phosphoglycerate mutase (Gpm1p) 
Phosphoglycerate mutase (Gpm1p) is a 27-kDa, cytoplasmic and cell surface-
associated protein of both yeast and hyphal forms of C. albicans [61,72]. As a 
cytoplasmic protein, Gpm1p converts 3-phosphoglyerate to 2-
phosphoglycerate during glycolysis and vice versa during gluconeogenesis . 
On the cell surface, Gpm1p binds the host complement Factor H, FHL-1 and 
plasminogen [61]. Binding of Factor H and FHL-1 by Gpm1p is a complement 
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evasion strategy of C. albicans. Presence of anti-Gpm1p antibodies in serum 
of human candidiasis patients indicate that Gpm1p is an immunogenic protein 
[73]. 
Gpm1p is encoded by the gene GPM1 (orf19.903). Expression of GPM1 is 
regulated by several conditions. GPM1 is downregulated when C. albicans is 
exposed to farnesol [74]. In addition, different antifungal agents have varying 
effects on the expression of GPM1. GPM1 mRNA increases during 
fluconazole exposure, but is downregulated when exposed to ketoconazole 
[75]. GPM1 gene is also regulated by C. albicans growth phase. GPM1 mRNA 
levels increase during exponential growth phase of the yeast form, then 
decrease to relatively low levels in stationary phase. GPM1 mRNA levels then 
decrease rapidly after dilution of late-exponential cells into fresh hyphal-
inducing media [76]. Moreover, the GPM1 transcript is induced in biofilm-
versus-planktonic cell culture [61,77]. GPM1 expression is also upregulated in 
a dual-species biofilm with S. aureus [78]. Morphogenetic transcriptional 
regulators also affect the expression of GPM1. GPM1 is regulated by the 
transcription factor Efg1p but not its homologue Efh1p. Furthermore, 
upregulation of GPM1 occurs during amino acid starvation which is dependent 
on Gcn4p, a transcriptional activator of amino acid biosynthetic gene. 
Moreover, deletion of GPM1 gene renders C. albicans unable to grow in 
gluocose. gpm1 deletion mutant grows only on ethanol and/or glycerol as 
carbon source/s [61]. 
 
1.2.1.3. Candida albicans translation elongation factor 1-alpha (Tef1p)  
Translation elongation factor 1-alpha (Tef1p) is a canonically important protein 
in eukaryotic protein synthesis. Tef1p binds guanosine-5’-triphosphate (GTP) 
and binds to aminoacyl transfer RNAs (tRNAs). The Tef1p-GTP-tRNA 
complex binds to the ribosome delivering the amino acids contributing to the 
elongation of the polypeptide. 
C. albicans Tef1p is a 50-kDa protein which is found in both cytoplasmic and 
cell surface components of the fungus [79]. Aside from its role in protein 
synthesis in the cytoplasm, cell-surface Tef1p binds to plasminogen [37]. 
Tef1p protein is encoded by two C. albicans genes TEF1 and TEF2 [80]. The 
TEF1 gene is upregulated in reconstituted human oral epithelium (RHE) 
model of oral candidiasis and in clinical oral candidiasis isolates [81,83,84]. In 
addition, TEF1 is induced upon phagocytosis by macrophage-like cells [82]. 
TEF1 is thought to be essential as no TEF1 disruptants were obtained by 
UAU1 method using the BWP17 strain [87].  
 
1.2.2. Complement evasion by bacterial pathogens 
Microbial pathogens have evolved immune evasion strategies to further the 
infection process. Immune evasion strategies by pathogens vary from 
masking themselves by binding host proteins to degrading host components 
by secreting degradative proteins. Bacteria such as Staphylococcus aureus 
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and Neisseria meningitidis are well known to evade the immune system which 
is the reason for their prevalence in nosocomial infections and leading cause 
of deaths in humans. By possessing secreted and cell wall-bound proteins, S. 
aureaus can block the three activation pathways of the complement system. 
Sbi [83,84], SCIN [85,86], Efb [84] and SSL-7 [89,90] are just some of the 
staphylococcal proteins which are effective inhibitors of the specific parts of 
the complement cascade either by binding complement components or 
degrading them. N. meningitidis binds Factor H to act as a cofactor for Factor 
I in inactivating the opsonin C3b [91,92].  
 
1.2.3. Bacterial pathogens and vitronectin 
Microbial pathogens utilize the various functions of vitronectin for their 
proliferation inside the human body. The terminal complement complex (TCC) 
inhibition and adhesive properties of vitronectin make it a useful human host 
protein for microbial pathogens in evading the immune system and invading 
host tissues. Bacterial pathogens such as Haemophilus influenzae [93-95], 
Haemophilus ducreyi [96], Neisseria meningitidis [97], and Moraxella 
catarrhalis [98-99] have serum resistance due to their ability to bind vitronectin 
from human plasma. Bound vitronectin on the surface of the bacterial cells 
inhibits the formation of the TCC which prevents the lysis of the cells [2,3].  
In addition, bacterial pathogens bind vitronectin to attach to human cells for 
subsequent colonization and invasion. Escherichia coli, S. aureaus and 
Streptococcus pneumoniae utilize the adhesive property of vitronectin to 
attach to different types of host cells [100]. Adhesins on the surface of these 
bacterial pathogens bind to the heparin-binding domains on the vitronectin 
molecule which, in turn, binds to host cells through the integrin-binding Arg-
Gly-Asp (RGD) motif. As an example, binding of vitronectin to gain access to 
epithelial and endothelial cells is a mechanism employed by S. pneumoniae. 
When vitronectin is bound to the integrin αvβ3 on host cells via the RGD motif, 
S. pneumoniae can bind to vitronectin through its heparin binding domains. By 
binding to the heparin binding domain of vitronectin, S. pneumiae can trigger 
its internalization by activating the signalling pathway which involves the 
integrin-linked kinase (ILK), phosphatidylinositol 3-kinase (PI3K) and protein 
kinase B (Akt) [101].  
 
1.2.4. Bacterial pathogens and plasminogen 
Plasminogen is utilized by microbial pathogens for tissue invasion by 
degrading components of extracellular matrix [102], and for immune evasion 
by degrading the opsonin C3b. Bacterial pathogens like Leptospira 
interrogans [103-105], Borrelia burgdorferi [106], Salmonella enterica serovar 
Typhimurium [107], and Streptococcus pneumoniae [108] bind plasminogen 
to degrade components of the extracellular matrix. The bound plasminogen is 
activated either by the human plasminogen activators or produced by the 
bacteria themselves [17]. The bound plasmin maintains its activity in 
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degrading substrates. Recently, it has been shown that pathogens bind 
plasminogen, not only for tissue invasion, but also for evasion of the 
complement system. Bacteria-bound plasminogen, when converted to 
plasmin, binds to C3 and C3b and degrade them, thereby avoiding recognition 
by phagocytes. This mechanism of immune evasion has been shown for 
bacterial pathogens S. aureaus [84,109], Bacillus anthracis [11] and 
Francisella tularensis [18] but not for fungal pathogens. 
 
1.3. Objectives of the study 
In this dissertation two of the virulence mechanisms of C. albicans were 
investigated: evasion of the innate immune system, and attachment to human 
host cells. It was therefore the aim of this thesis to elucidate the roles of 
specific C. albicans surface proteins in the virulence and immune evasion of 
the fungus. In this study, two fungal proteins were selected and characterized 
in detail. 
Specificially, this thesis aimed to: 
• Determine human host ligand for C. albicans Gpm1p 
• Elucidate the function and mechanism of C. albicans Gpm1p-human 
host ligand interaction 
• Clone, express and purify recombinant C. albicans Tef1p 
• Determine human host ligand for C. albicans Tef1p 
• Elucidate the function and mechanism of C. albicans Tef1p-human 
host interaction 
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2. MATERIALS AND METHODS 
 
2.1. Materials 
 
2.1.1. Human sera and cells 
Normal human serum (NHS) samples were obtained from healthy laboratory 
personnel. Sera were stored at –80°C prior to use. Complement was 
inactivated from the serum either by adding ethylenediaminetetraacetic acid 
(EDTA) to a final concentration of 10 mM (NHS-EDTA) or by heat inactivation 
at 56°C for 30 min (hiNHS). Human umbilical vein endothelial cells (HUVEC) 
and keratinocytes (HaCaT) cells were purchased from ATCC (Vanassas, VA, 
USA). The use of human neutrophils in this study was conducted according to 
the principles expressed in the Declaration of Helsinki. All protocols used in 
this study were approved by the local ethics committee of the University of 
Jena under the permit no. 2207-01/08. Written informed consent was provided 
by all study participants. Neutrophils were isolated from whole blood using 
PolymorphPrep (Axis-Shield PoC AS, Oslo, Norway) gradient centrifugation 
using the manufacturer’s instructions. 
 
2.1.2. Chemicals, reagents and plastic materials  
Unless specified otherwise, chemicals and reagents were purchased in the 
highest available quality from Sigma or Roth. RPMI1640 medium, Dulbecco’s 
modified eagle medium (DMEM), and Dulbecco’s phosphate buffered saline 
(DPBS) were from Lonza (Verviers, Belgium). MaxiSorp and PolySorp 
microtiter plates were manufactured by Nunc, New York, NY, USA.  
 
2.1.3. Microbial media and supplements 
E. coli cells were cultivated in sterile LB (Luria Broth) medium (10 g bacto-
tryptone, 5 g bacto-yeast extract, 10 g NaCl, pH adjusted to 7.2) or LB agar 
plates (LB medium + 15 g/l agar). To select for colonies containing the 
desired plasmid, LB medium was supplemented with 50-100 µg/ml ampicillin 
(Invitrogen). 
Media used for C. albicans cultivation were YPD broth [2% glucose, 2% 
peptone, 1% yeast extract; in w/v]. C. albicans GPM1 strains were YPGE 
broth [3% glycerol, 2% ethanol, 2% peptone, 1% yeast extract; in w/v] or SG 
broth [3% glycerol, 2% peptone from casein, 1% yeast extract; in w/v]. Agar 
media were prepared as above with addition of 1.5%  (w/v) agar. 
For selection purposes C. albicans cells were spread on SD agar (2% 
dextrose, 0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% agar) 
supplemented with 20 mg/ml arginine, histidine and/or uridine as required . 
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2.1.4. Equipment 
The laser scanning microscopes used were LSM 510 META and LSM 710 
(Zeiss, Jena, Germany). Flow cytometry was performed by BD LSR II (Becton 
Dickinson, Heidelberg, Germany). The ELISA reader used was Multiskan 
Ascent (Thermo Scientific, Thermo Labsystems, Finland). The Biacore 3000 
instrument and sensor chips were from Biacore AB, Uppsala, Sweden. Äkta 
purifier and Äkta FPLC used for protein purifications were from GE Healthcare 
Life Sciences. 
 
2.1.5. Purified and recombinant proteins 
Plasma proteins Factor H, Factor I, C3, C3a, C3b, C3c, C3d and iC3b were 
purchased from Complement Technology, Inc. (Texas, USA). C4BP was 
provided by Prof. Dr. Ana Blom (Department of Laboratory Medicine, Malmö 
University Hospital, Sweden). Recombinant proteins Efb, C3d and C3dg were 
provided by Sascha Böhm (Department of Infection Biology, HKI, Jena, 
Germany). Plasminogen and tissue-type activator (tPa) were purchased from 
Haemochrom Diagnostica GmbH (Essen, Germany). Extracellular matrix 
proteins fibronectin, laminin, fibrinogen, collagen I, collagen III and collagen IV 
were purchased from Calbiochem while vitronectin was from Becton 
Dickinson. 
 
2.1.6. Antibodies 
Primary antibodies used in immunodetection methods were either generated 
in this study or bought as specified in Table 2. HRP-coupled secondary 
antibodies (Table 2) used for enzyme-linked immunosorbent assay (ELISA) 
and Western blotting experiments were purchased from Dako Denmark 
(Glostrup, Denmanrk). Fluorescent dye-labelled secondary antibodies (Table 
2) used in flow cytometry and laser scanning microscopy experiments were 
purchased from Invitrogen Molecular Probes (Life Technologies GmbH, 
Darmstadt, Germany). 
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Table 2. Antibodies used in this study. 
Primary antibodies Secondary antibodies 
Name Specifity Name 
Rabbit Gpm1p antiserum 
(this study) 
Gpm1p (polyclonal) Alexa 647®-conjugated rabbit 
anti-goat 
Rabbit vitronectin antiserum 
(Complement Technology) 
Vitronectin (polyclonal) Alexa 647®-conjugated goat 
anti-mouse 
Mouse fibronectin antibody 
(Sigma-Aldrich) 
Fibronectin (monoclonal) Alexa 488®-conjugated goat 
anti-rabbit 
Mouse laminin antibody 
(Sigma-Aldrich) 
Laminin (monoclonal) Alexa 647®-conjugated rabbit 
anti-goat 
Rabbit fibrinogen antiserum 
(Calbiochem) 
Fibrinogen (polyclonal) Alexa 488®-conjugated goat 
anti-rabbit 
Mouse collagen I antibody 
(Sigma-Aldrich) 
Collagen I (monoclonal) HRP-coupled goat anti-rabbit 
Mouse collagen III antibody 
(Sigma-Aldrich) 
Collagen III (monoclonal) HRP-coupled rabbit anti-goat 
Mouse collagen IV antibody 
(Sigma-Aldrich) 
Collagen IV (monoclonal) HRP-coupled goat anti-
mouse 
Mouse Gpm1p antibody 
(this study) 
Gpm1p (monoclonal)  
Mouse vitronectin antibody 
(Acris Antibodies GmbH) 
Vitronectin (monoclonal)  
Mouse penta-His antibody 
(Qiagen) 
His-tag (monoclonal)  
Goat Factor H antiserum 
(Complement Technology) 
Factor H (polyclonal)  
Rabbit C4BP antiserum 
(Prof. Ana Blom) 
C4BP (polyclonal)  
Rabbit C3d antiserum 
(Dako) 
C3d (polyclonal)  
Goat C3 antiserum 
(Complement Technology) 
C3 and C3b (polyclonal)  
Goat plasminogen antiserum 
(Acris Antibodies GmbH) 
Plasminogen (polyclonal)  
Rabbit Tef1p antiserum 
(this study) 
Tef1p (polyclonal)  
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2.2. Methods 
 
2.2.1. Microbiological methods 
 
2.2.1.1 Strains used 
 
Pichia pastoris 
Pichia pastoris X33 was used to produce the recombinant His-tagged C. 
albicans Gpm1p described in Poltermann et. al (2007) [61]. 
 
Escherichia coli  
One Shot® TOP10 competent E. coli (Invitrogen) that lacks T7 RNA 
polymerase was used for characterization, propagation and maintenance of 
the plasmid construct for cloning the C. alibans TEF1 gene. The E. coli 
expression strain BL21 Star™ (DE3) (Invitrogen) was used for protein 
expression. E. coli DH5α was used to propagate plasmids used in cloning, 
deletion and reintegration of TEF1 in C. albicans.  
 
Candida albicans 
The C. albicans strains used and generated in this study and their 
corresponding genotypes and descriptions are listed in Table 3. 
 
2.2.1.2. Cultivation and conservation of microbial strains 
During the cloning experiments, E. coli strains were grown in LB medium at 
37°C overnight with shaking at 180 rpm. For use in various experiments, C. 
albicans TEF1 strains were grown in YPD broth overnight in a rotary shaker at 
180 rpm at 30 °C. C. albicans GPM1 strains were grown in SG or YPGE broth 
medium at 180 rpm at 30 °C. Stock cultures of generated C. albicans TEF1 
strains were stored at -80 °C in YPD broth with 20% glycerol. Cultures for 
experiments were maintained on YPD or SG agar plates at 4 °C and colonies 
were restreaked on fresh agar plates every 2 weeks. 
 
2.2.1.3. C. albicans growth curves in liquid and agar media 
Aliquots of YPD broth overnight cultures of C. albicans TEF1 strains were 
washed twice in phosphate buffered saline (PBS) and cells with optical 
density at 600 nm (OD600 nm)=0.1 were inoculated in YPD broth (for liquid 
culture growth curve) or 10-fold serial dilutions in 5 μl (covering a range of 
106–101 cells) were spotted onto YPD agar (for solid medium growth). Liquid 
culture growth curve experiment flasks were incubated for 14 h at 30 °C with 
collection of samples every hour for the measurement of optical density at 600 
nm (OD600 nm). YPD agar plates were incubated for 2-3 days at 30 °C or 37 
°C. 
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2.2.1.4. C. albicans stress susceptibility 
Aliquots of YPD broth overnight cultures of C. albicans TEF1 strains were 
washed twice in phosphate buffered saline (PBS) and 10-fold serial dilutions 
in 5 ml (covering a range of 106–101 cells) were spotted onto YPD agar 
containing calcofluor white (6.7 nM), congo red (20 µg/ml), SDS (0.004%), 
NaCl (1.5 M), sorbitol (1.0 M), menadione (25 µM), H2O2 (2 µM), t-BOOH (2 
mM); and hygromycin (0.5 mg/ml). Plates were incubated for 2-3 days at 30 
ºC. 
 
Table 3. C. albicans strains used in this study. 
Strain Genotype Reference 
SC5314 Wild type [111] 
gpm1Δ 
 
gpm1::hisG-URA3-hisG/GPM1, 
ura3::imm434/ura3::imm434 
[61] 
gpm1Δ/Δ gpm1::hisG/gpm1::hisG-URA3-hisG, 
ura3::imm434/ura3::imm434 
[61] 
gpm1Δ/Δ::GPM1 gpm1::hisG/GPM1::hisG-URA3-hisG, 
ura3::imm434/ura3::imm434 
[61] 
BWP17 ura3 ::λimm434/ura3 ::λimm434  
arg4::hisG/arg4::hisG his1::hisG/his1::hisG 
[112] 
tef1Δ TEF1/tef1::ARG4 This study 
tef1Δ/Δura- tef1::ARG/tef1::HIS This study 
tef1Δ/Δ tef1::ARG/tef1::HIS+CIp10 (URA) This study 
tef1Δ/Δ::TEF1 tef1::ARG/tef1::HIS+CIp10+TEF1 (orf19.1435, URA) This study 
BWP17+CIp30 ura3 ::λimm434/ura3 ::λimm434  
arg4::hisG/arg4::hisG his1::hisG/his1::hisG + CIp30 
[113] 
 
 
2.2.2. Molecular Biological Methods 
  
2.2.2.1. C. albicans TEF1 cloning 
The TEF1 gene was amplified from the chromosomal DNA of C. albicans 
SC5314 isolated using MasterPureTM yeast DNA purification kit (Epicentre 
Biotechnologies). Production of blunt-end polymerase chain reaction (PCR) 
product was done through amplification of TEF1 from the genomic DNA 
template using the primers: CaTef1pET101For and CaTef1pET101Rev 
(Table 4) and the program: initial denaturation, 98 °C for 30 sec; denaturation, 
98 °C for 10 sec; annealing, 65 °C for 30 sec, elongation, 72 °C for 45 sec; 
and final extension, 72 °C 10 min; cyles, 30.  The following recipe was used 
for 20-μl reaction: DNA template, 0.4 μl; 10mM DNTPs, 0.4 μl; 2.5 μM forward 
primer, 0.5 μl; 2.5 μM reverse primer, 0.5 μl; 5X HF Buffer, 4 μl; Phusion 
polymerase, 0.2 μl; and water, 14 μl. Then TOPO cloning reaction was done 
to insert blunt-end PCR product to the expression plasmid pET101/D-TOPO® 
using manufacturer’s instructions. Briefly, 2 µl of successfully amplified TEF1 
PCR products were mixed with 1 µl NaCl, 2 µl sterile water and 1 µl TOPO 
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vector, and incubated for 5 min, before the reaction mixture was transformed 
into One Shot TOP10 E. coli competent cells. Transformation of pET101-
CaTef1 in E.coli competent cells was done using manufacturer’s instructions. 
Colony PCR of grown colonies to select positive transformant was done using 
Quiagen HotStar Taq Master Mix Kit using the following recipe: 12.5 μl 
HotStar Taq Master Mix, 0.625 μl of 10 μM forward primer, 0.625 μl of 10 μM 
reverse primer, and 10.25 μl water. Program for colony PCR used was as 
follows: initial denaturation, 95 °C for 15 min; denaturation, 94°C for 1 min; 
annealing, 65°C for 1 min; elongation, 72 °C for 1 min; and final elongation, 
72 °C for 10 min; cycles, 30. PCR products were analyzed by agarose gel 
electrophoresis and positive colony was purified and conserved. Transformed 
E.coli cells with correct pET101-CaTef1 were then cultivated on LB medium 
containing 50 µg/ml ampicillin for 24 h at 37 °C. TEF1-containing clones were 
cultivated for plasmid isolation. 
Plasmid isolation was done by cultivating E. coli transformants 
harboring pET101-CaTef1 in 3 ml LB media (supplemented with ampicillin) 
overnight at 37°C with shaking. Plasmids were isolated using Spin Plasmid 
Mini Two Kit (Invitek) following the manufacturer’s instructions. Briefly, cells 
were harvested, resuspended in 250-μl resuspension buffer, and lysed by 
lysing buffer. Thereafter a neutralization buffer was added, and the mixture 
was centrifuged at 3000 x g for 10 min. The supernatant was applied to a 
QIAprep spin column, and the plasmid DNA was bound to the column through 
centrifugation at 3000 g for 30 s. Before elution of the plasmid DNA in 30 µl 
water, the column was washed with wash buffer. 
Transformation into E. coli BL21 Star (DE3) expression strain was done by 
following manufacturer’s instructions. Briefly, 10 ng plasmid DNA (in 2 µl 
water) were added to thawed BL21 Star cells, and incubated for 30 min on 
ice. After heat-shock, the cells were incubated in SOC medium (Invitrogen), 
and plated on LB plates containing ampicillin. Positive transformants were 
screened using colony PCR as described above. 
 
2.2.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyze amplified DNA fragments. 
Samples were mixed with 6 x DNA loading dye solution (Fermentas), and 
separated using 1% TBE (890 mM tris, 890 mM boric acid, 20 mM EDTA) 
agarose gel containing 0.1 µg/ml ethidium bromide. SmartLadder 
(Eurogentec) was used as marker. DNA bands were visualized under UV light 
in a gel documentation system (BioRad). 
 
2.2.2.3 DNA sequencing 
In order to confirm that TEF1 was in frame with the C-terminal His-tag, and to 
exclude mutations in the sequence, plasmids containing the construct were 
sequenced via Sanger sequencing using an ABI PRISM® 3130x Genetic 
Analyzer (Applied Biosystem).  
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2.2.2.4. Southern blotting 
Ten μg of chromosomal DNA of C. albicans SC5314 and TEF1 deletion 
strains were cut with PciI. DNA fragments were separated on a 1% (wt/vol) 
agarose gel and blotted onto a Hybond N+ nylon membrane (GE Healthcare, 
Freiburg, Germany). Labeling of the DNA probe was performed using the 
PCR digoxigenin (DIG) labeling mix (Roche Applied Science, Mannheim, 
Germany). For hybridization and detection of DNA-DNA hybrids, the DIG 
Easy Hyb and the CDP-Star ready-to-use kit (Roche Applied Science, 
Mannheim, Germany) were used according to the manufacturer’s instructions. 
2.2.2.5. C. albicans TEF1 deletion 
The generation of TEF1 knock-out and reintegration strains were done under 
the supervision of Pedro Miramón (Department of Molecular Pathogenicity 
Mechanisms, Leibniz Institute for Natural Product Research and Infection 
Biology, HKI). The tef1Δ/Δ homozygous null mutant was generated using a 
PCR-based gene disruption technique [116]. Starting with the Arg-, His- and 
Ura-auxotrophic parental strain BWP17, the complete open reading frames 
(ORFs) of both TEF1 alleles were replaced with polymerase chain reaction 
(PCR)-amplified ARG4 and HIS1 disruption cassettes flanked by 104 base 
pairs of target homology region. Two sequential transformations using the 
improved lithium-acetate method were applied for both disruption cassettes. 
Primers TEF1-KOfwd and TEF1-KOrev (Table 4) were used for generation of 
the ARG4 and HIS1 deletion cassettes with the pFA-ARG4 and pFA-HIS1 
plasmids as templates. Resultant deletion cassettes were used to sequentially 
delete both copies of TEF1 (orf19.1435). The resultant Ura-auxotrophic 
mutant was rendered prototrophic for uridine by transformation with the NcoI-
linearized plasmid CIp10, which harbors the URA3 gene and stably integrates 
at the RPS10 locus. The correct deletion of both alleles and integration of 
CIp10 was verified by colony PCR using target gene and 
disruption/integration cassette flanking and internal primers: TEF1-disrptnup, 
TEF1-disrptndown, ARG4-F1, ARG4-R1, HIS1-F1, HIS1-R1, URA3-F2 and 
RPF-F1 (Table 4), respectively.  
Additionally, Southern blot analysis using a 517-base-pair PCR product, 
generated with the primers CaTEF1Int-Rev and CaTEF1Int-Fwd from C. 
albicans SC5314 genomic DNA, as a probe on PciI-digested genomic DNA 
was used to confirm deletion of TEF1. 
For the generation of a tef1Δ/Δ::TEF1-reconstituted strain, the open reading 
frame of TEF1 as well as 406 base pairs of upstream and 2,145 base pairs of 
downstream sequence were amplified from SC5314 genomic DNA with the 
Phusion High- Fidelity DNA Polymerase Kit (Finnzymes) using the SalI 
restriction site-containing primer CaTEF1Complmnt-Fwd and MluI restriction 
site-containing primer CaTEF1Complmnt-Rev (Table 4). The resulting PCR  
product was first subcloned into pCR2.1 for easy digestion generating pCR-
TEF1. The plasmid pCR-TEF1 was screened for right insertion by digesting 
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with NcoI and SalI restriction enzymes. pCR-TEF1 was then digested with 
SalI, MluI and PstI. Pst I was additionally used to distinguish the TEF1 insert 
and the rest of the plasmid since the SalI-MluI digested plasmid has two 
fragments of the same size. The digested pCR-TEF1 was then further purified 
with the QIAquick PCR Purification Kit (Qiagen). In parallel 0.3 μg/μl of 
plasmid CIp10 was digested with SalI and MluI restriction enzymes then heat 
inactivated by an incubation at 65 °C for 20 min. The linearized plasmid was 
dephosphorylated with calf intestinal alkaline phosphatase (New England 
BioLabs) and gel extracted using the QIAquick Gel Extraction Kit (Qiagen). 
The TEF1 insert and CIp10 vector were then ligated for 30 min at 22 °C using 
the Rapid DNA Ligation Kit (Fermentas). Five μl of ligation product was used 
for the transformation of E. coli DH5α and positive clones were selected on 
LB agar plates supplemented with 50 mg ml-1 Ampicillin. Plasmid CIp10 
carrying TEF1 was re-isolated using plasmid miniprep (peqlab) and midiprep 
(Qiagen) kits and confirmed by control digestions with SalI and MluI and 
sequencing. The final plasmid was then digested with StuI prior to 
transformation into the uridine auxotrophic C. albicans strain tef1Δ/Δura-. 
Positive clones were selected on SD agar plates without amino acids. Correct 
integration was verified by PCR on whole yeast colonies using primers RPF-
F1 and URA3-F2. 
 
Table 4. Primers used in this study. 
Primer Sequence (5’3’) Reference 
CaTef1pET101For caccatgggtaaagaaaaaactcac This study 
CaTef1pET101Rev tttcttagcagctttttgagcagc This study 
TEF1KOfwd 
aaagtaaagtaaagaaaaaaaaattttccctcgtcatcttgattttta
cttcttcttcttcttcttctttttcctttcttcacacattatagtcataatcaatc
gaagcttcgtacgctgcaggtc 
This study 
TEF1KOrev 
tttttttaaaatatatattatatttcaaatataataagaaaataaactaa
ataaatgaatacaaaataaaaactctaacagatcttacataatattc
aactagctctgatatcatcgatgaattcgag 
This study 
TEF1-disrptup tttttgggtttttgttgttt This study 
TEF1-disrptdown ttcaaaacaaaccggactac This study 
TEF_2 aatggtttgtcggttggtctggtt This study 
TEF_3 gaaccatccaccaactgtccat  
CaTEF1Int-Fwd gacgctattgaaccacca This study 
CaTEF1Int-Rev ccatcttgacgatagca This study 
CaTEF1Complmnt-Fwd aaaaaagtcgacgctgatacggcatgccag This study 
CaTEF1Complmnt-Rev aaaaaaacgcgttattagcaacttagacaatccctg This study 
ARG4-F1 ggatatgttggctactgatttagc [113] 
ARG4-R1 aatggatcagtggcaccggtg [113] 
HIS1-F1 ggacgaattgaagaaagctggtgcaaccg [113] 
HIS1-R1 caacgaaatggcctcccctaccacag [113] 
URA3-F2 ggagttggattagatgataaaggtgatgg [113] 
RPF-F1 gagcagtgtacacacacacatcttg [113] 
Underlined nucleotides of TEF1KOfwd and TEF1KOrev primers indicate pFA-ARG4 and pFA-HIS1 annealing 
regions; underlined nucleotides of primer CaTEF1Complmnt-Fwd indicate SalI restriction site and of primer 
CaTEF1Complmnt-Rev indicate MluI restriction site. 
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2.2.3. Protein Biochemistry and Immunological Methods 
 
2.2.3.1. ELISA binding studies 
 
Binding of extracellular matrix (ECM) proteins to Gpm1p 
To determine the binding of different extracellular matrix (ECM) proteins to 
Gpm1p, the enzyme-linked immunosorbent assay was used.  A 96-well 
microtiter plate was coated with 0.25 µg of Gpm1p or human serum albumin 
(HSA) in carbonate-bicarbonate buffer overnight at 4 ̊C.  After washing one 
time with distilled deionized water and one time with the washing buffer 
(phosphate-buffered saline + 0.05% Tween 20), the plate was blocked with 
the blocking solution (4% milk powder + 2% bovine serum albumin in 
phosphate-buffered saline) at room temperature (RT) for 2 hour.  The plate 
was then washed two times with washing buffer.  Seven hundred fifty ng of 
ECM proteins (fibronectin, vitronectin, laminin, fibrinogen, collagen I, collagen 
III or collagen IV) were added to the plate and incubated for 1 hour at RT. 
After washing two times with washing buffer, the corresponding primary 
antibody (1:1000 in blocking solution) as listed in Table 2 was added to the 
plate.  Horseradish peroxidase-conjugated secondary antibody (1:2000 in 
blocking solution) was added after washing the plate two times with washing 
buffer.  The bound secondary antibody was detected using 3,3’,5,5’-
tetramethylbenzidine (TMB) and stopped with 2 M H2SO4.  The absorbance of 
the generated color was measured in an ELISA plate reader at 450 nm. 
 
Dose-dependent binding and effects of heparin and NaCl 
 The binding of vitronectin to Gpm1p was characterized according to 
concentration dependency and effects of heparin and NaCl.  Concentration-
dependent binding of vitronectin to Gpm1p was measured using the method 
described above with different amounts of added vitronectin (0, 0.25, 0.5 and 
1.0 µg).  Effect of heparin was measured by pre-incubating vitronectin with 
increasing amounts of heparin (0, 0.01, 0.1 and 1.0 µg) for 30 min at 37  ̊C.  
To determine the effect of divalent cations to the binding of vitronectin to 
Gpm1p, increasing concentrations of MgCl2 (0, 0.1, 0.5 and 1.0 mM) was pre-
incubated with vitronectin before adding to Gpm1p as described above.  The 
same procedure was used to determine whether the binding was based on 
ionic strength with the addition of increasing concentrations of NaCl (0, 50, 
100, 150, 300 and 600 mM). 
 
Binding of complement proteins to Tef1p 
The binding of different complement proteins to immobilized Tef1p was done 
using the steps in Section 2.2.3.1. but using Factor H, C4BP, C3d, C3dg, iC3b 
or plasminogen as ligand, and Tef1p was immobilized instead of Gpm1p.  
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Primary and secondary antibodies used to detect the corresponding bound 
ligands are listed in Table 2. 
 
Binding of plasminogen to Tef1p 
Dose-dependent binding of plasminogen to immobilized Tef1p was done 
using the steps in Section 2.3.1.2 but using plasminogen concentrations of 0, 
1.0, 5.0, and 10 μg/ml. To determine if lysine residues are involved in the 
binding of plasminogen to Tef1p, various concentration of the lysine analog ε-
aminocaproic acid (ε-ACA) (0, 0.1, 0.2, 0.4, and 1.0 mM) was first incubated 
with plasminogen (5.0 μg/ml) for 30 min at 37 °C before adding to immobilized 
Tef1p. Bound plasminogen was detected by goat plasminogen antiserum 
followed by HRP-coupled rabbit anti-goat IgG.  
 
2.2.3.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Protein mixtures were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) according to method of Laemmli [114] using a 
Biometra system. Protein samples were diluted in loading buffer (0.31 M 
tris/base pH 6.8, 5% SDS, 50% glycerol, 0.001% bromphenol blue) or 
denatured by β-mercaptoethanol-containing Roti®-Load 1 (Roth) at 95°C for 
5 min. Electrophoresis was performed using 4 % stacking gels (3.0 ml distilled 
water, 1.25 ml 0.5 M tris/HCl pH 6.8 plus 0.4% SDS, 0.650 ml acrylamide-
bisacrylamide 30%, 25 µl 10% ammonium persulfate (APS), 5 µl N,N,N',N'- 
tetramethylendiamine (TEMED) and 8% or 12% running gels (for 12%: 
5.25 ml distilled water, 5.25 ml 1.5 M tris/base pH 8.8 plus 0.4% SDS, 5.0 ml 
acrylamide-bisacryamide 30%, 50 µl 10% APS, 10 µl TEMED) in running 
buffer (3% tris/base, 14.4% glycine, 1% SDS). 
 
2.2.3.3. Silver staining 
To detect proteins after protein electrophoresis, silver staining was performed. 
Gels were fixed in 30% acetic acid plus 20% ethanol for 45 min, washed twice 
with 20% ethanol and sensitized in 0.02% sodium thiosulfate for 2 min. Then 
the gels were rinsed twice for 1 min in distilled water, stained for 20 min with 
0.2% silver nitrate, and rinsed twice in distilled water again. Gels were 
developed using developer (0.00007% formaldehyde (37%), 3% sodium 
carbonate, 0.001% sodium thiosulfate), and the reaction was stopped by 
rinsing with stop solution (2.5% acetic acid, 50% tris/base ). 
 
2.2.3.4. Coomassie blue staining 
Coomassie staining (Page Blue, Fermentas) was performed according to the 
manufacturer’s instructions. 
 
2.2.3.5. Western blotting 
To detect specific proteins after SDS-PAGE, Western blotting was performed. 
Gels were transferred to a nitrocellulose membrane (Protran), by placing them 
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in the transfer cassette, and immersing them in transfer buffer (0.045 M tris, 
0.039 mM glycine, 20% methanol, 0.1% SDS), and allowing to run at 48 mA 
for 70 min. Membranes were then blocked in blocking buffer (1% bovine 
serum albumin [BSA], 4% milk powder, 0.1% Tween 20) for 1 h at room 
temperature or overnight at 4°C, and incubated with appropriate primary and 
secondary antibodies (Ab) for 1 h at room temperature, washed with wash 
buffer (0.05% Tween in phosphate buffered saline (PBS) II (137 mM NaCl, 
2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4), and developed with 
enhanced chemiluminescence (ECL)-substrate solution (AppliChem) with a 
DNR BioImaging System (MF-ChemBIS 3.2). 
 
2.2.3.6. Surface plasmon resonance (SPR)  
Plasminogen binding to immobilized Tef1p was analyzed in real time by 
surface plasmon resonance using Biacore 3000 at 25°C in 150 mM PBS. 
Tef1p was immobilized on a CMD 500M sensor chip (Xantec) by standard 
amino coupling chemistry following the manufacturer´s protocol. Plasminogen 
(at concentrations of 0, 100, 200 or 400 nM) was injected at a flow rate of 
5 µl/min. The effect of on the binding of plasminogen to Tef1p was also 
investigated using surface plasmon resonance. Plasminogen was incubated 
with 0, 0.5, 1.0, or 2.0 nM ε-ACA prior to injection to immobilized Tef1p as 
above. 
 
 
2.2.3.7. Protein expression and purification 
 
2.2.3.7.1. Gpm1p 
Recombinant Gpm1p was expressed and purified in Pichia pastoris using the 
procedure of Poltermann et al. (2007) [61]. 
 
2.2.3.7.2. Tef1p 
One colony of freshly-grown transformant was inoculated into 10 ml LB with 
ampicillin (100 µg/ml) overnight at 37 ˚C with shaking until it reached OD600 = 
1-2. Two ml of grown culture were then inoculated into 100 ml LB+Amp 
medium at 37 ˚C with shaking until OD600 = 0.5 (2-3 h). One mM IPTG was 
added to induce expression for 4-6 hours. Cells were collected by 
centrifugation at 3000 x g for 10 min at 4 ˚C.  
 
Disruption, washing and isolation of inclusion bodies 
Pellet was resuspended from 100 ml E. coli culture in 4 ml Lysis Buffer (50 
mM potassium phosphate, 400 mM NaCl, 100 mM KCl, 10% glycerol, 0.5% 
Triton X-100, and 10 mM imidazole; pH=7.8) with 4 µl Benzonase and 80 µl 
Lysozyme (10 mg/ml). Sample was frozen in liquid nitrogen and then thawed 
at 42 ˚C. This step was repeated twice. Cells were disrupted with sonication 
(3 x 30 sec.) then centrifuged at high speed for 10 min. at 4  ̊C. Pellet was 
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resuspended in 3 ml cold Isolation Buffer (2 M urea, 0.02 M Tric-HCl, 0.5 M 
NaCl, and 2% Triton X-100; pH=8.0) then centrifuged at high speed for 10 
min. at 4  ̊C. This was repeated twice. 
 
Solubilization and sample preparation 
Pellet was resuspended in 5 ml Binding Buffer (0.02 M Tris-HCl, 0.5 M NaCl, 
0.005 M imidazole, 6 M guanidine hydrochloride, and 0.001 M ß-
mercaptoethanol; pH=8.0) then rolled for 30-60 min. at RT. Sample was 
centrifuged for 15 min. at high speed at 4  ̊C. Remaining particles were 
removed by passing the sample through a 0.22 or 0.45 µm filter. 
 
Preparation of the column 
HisTrap HP 1 ml column was washed with 5 ml filtered distilled deionized 
water at RT using a peristaltic pump at 5 min at 1.0 ml/min. The column was 
then equilibrated with 5-10 ml Binding Buffer (5-10 min at 1.0 ml/min). 
 
Purification and refolding 
Sample was loaded at rate of 0.5 ml/min into the column and then the column 
with sample was washed with 10 ml Binding Buffer at RT. Then, the column 
was washed with 10 ml Washing Buffer (0.02 M Tris-HCl, 0.5 M NaCl, 0.02 M 
imidazole, 6 M urea, and 0.001 ß-mercaptoethanol; pH=8.0). After the normal 
water washing step of Äkta purifier, Tubing A was placed in Washing Buffer 
and Tubing B in Refolding Buffer (0.02 M Tris-HCl, 0.5 M NaCl, 0.02 M 
imidazole, and 0.001 M ß-mercaptoethanol; pH=8.0). Column was placed in 
the appropriate Column Position on the Äkta. Loaded protein was refolded in 
the column by using linear gradient function (100% target for B) for 30 ml (60 
min at 0.5 ml/min) then continued washing with  5 ml (10 min at 0.5 ml/min) 
Refolding Buffer after the gradient came to its endpoint. Tubing A was then 
placed in Refolding Buffer and Tubing B in Elution Buffer (0.02 M Tris-HCl, 0.5 
M NaCl, 0.5 M imidazole, and 0.001 M ß-mercaptoethanol; pH=8.0). The 
system was run with 0% B until UV went down to 0. The refolded protein was 
then eluted (100% target for B) for 10-20 ml (20-40 min at 0.5 ml/min). Further 
elution was done for 5 ml more or until UV became near 0. The target for B 
was brought down to 0% then the column was removed from the Äkta purifier. 
Eluted protein was desalted using desalting column (Disposable PD-10, GE 
Healthcare Life Sciences) and  concentrated using centrifugal filter units 
(Millipore). Buffer was exchanged to DPBS during desalting and 
concentration. Protein concentration of purified Tef1p was determined by 
NanoDrop, and the purity was analyzed by SDS-PAGE, and silver staining or 
Western blotting. 
 
2.2.3.8. Generation of protein specific antibodies 
Gpm1p mouse monoclonal antibodies were kindly generated by the laboratory 
of Prof. Dr. Reinhard Wallich (Universitätsklinikum Heidelberg) after providing 
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them with purified recombinant Gpm1p. Tef1p rabbit antisera were obtained 
from David’s Biotechnologie after submitting purified recombinant Tef1p. 
 
2.2.3.9. Detection of Tef1p on the surface of C. albicans cells 
The presence of Tef1p on the surface of both yeast and true hyphal forms of 
C. albicans was detected using the generated Tef1p rabbit antiserum. A 
colony of GFP-expressing C. albicans was inoculated in YPD broth at 30 °C 
overnight. Cells from this culture were used for the subsequent experiments. 
C. albicans true hyphal cells were obtained by incubating yeast cells in YPD 
broth for 1.5 h at 37 °C. C. albicans yeast or hyphal cells (104) were 
inoculated on 14-mm coverslip in DPBS and allowed to adhere for  2 h. After 
washing twice with DPBS+0.05% Tween 20, C. albicans cells were incubated 
with Tef1p rabbit antiserum for 1 h at RT. Alexa Fluor® 647-conjugated goat 
anti-rabbit was used as secondary antibody after washing with DPBS+0.05% 
Tween 20. The coverslips were observed for fluorescence under the laser 
scanning microsopy (LSM). 
 
2.2.3.10. Biotinylation of proteins 
Biotinylated Gpm1p or BSA was generated using the EZ-Link Sulfo-NHS-
Biotinylation kit (Pierce) and following the manufacturer’s instructions. 
 
2.2.4. Functional Assays 
 
2.2.4.1. Acquisition of vitronectin from serum by C. albicans 
To determine if C. albicans can acquire vitronectin from serum, adsorption 
assay in combination with Western blotting or flow cytometry was carried out.  
Yeast cells (1.0 x 105) were washed twice in phosphate-buffered saline (PBS) 
and then incubated with 10% heat-inactivated normal human serum (hiNHS) 
for 30 min at 37 °C.  Normal human serum was heat-inactivated by incubating 
at 56   ̊C for 30 min.  For Western blotting, samples were mixed in loading 
buffer and heated at 99 °C for 10 min with shaking.  Then, samples were run 
in SDS-PAGE using 10% gel.  Proteins were transferred to nitrocellulose 
membrane and blocked in blocking solution (same as above) overnight at 
4  ̊C.  The membrane was then incubated in polyclonal rabbit anti-vitronectin 
antibody (1:1000 in blocking solution) for 1 h at RT. After washing three times 
(10 min each) in washing buffer (same as above), the membrane was 
incubated in horseradish peroxidase-conjugated goat anti-rabbit (1:2000 in 
blocking solution) for 1 h at RT. 
For flow cytometry, yeast cells were washed in PBS with 1% BSA before 
incubating in polyclonal rabbit anti-vitronectin antibody (1:100 in PBS + 1% 
BSA) for 30 min at RT.  After two washes, cells were incubated in Alexa-fluor 
647-labeled goat anti-rabbit IgG (1:200) for 30 min at RT.  Cells were then 
washed and examined by flow cytometry.  Forward and sideward scatters 
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were used for the identification of the cells, and fluorescent events of 10,000 
cells were counted. 
 
 
2.2.4.2. Blocking assays 
To determine if surface Gpm1p of C. albicans plays a role in the acquisition of 
vitronectin from human serum, blocking assays were done using Candida 
ELISA and flow cytometry.  Candida ELISA was carried out by coating 1.0 x 
105 yeast cells on 96-welll microtiter plate with carbonate-bicarbonate coating 
buffer overnight at 4  ̊C.  After blocking, wells were added with 10% hiNHS 
pre-incubated with varying amounts of recombinant Gpm1p (0, 0.1, 1.0 and 
10.0 µg) at 37 ̊C for 30 min.  The bound vitronectin was detected using the 
procedure described above.  Flow cytometric determination of the amount of 
vitronectin which bound to the yeast cells was done as above but with the pre-
incubation of hiNHS with varying amounts of recombinant Gpm1p. 
 
2.2.4.3. Gpm1p binding to human cells   
Determination of the binding of recombinant Gpm1p to both endothelial cells 
and keratinocytes was done using flow cytometry and laser scanning 
microscopy (LSM).  For the flow cytometry experiment, human cells were 
collected and washed with PBS+1%BSA  twice.  Recombinant Gpm1p was 
added to the cells at increasing amounts (0, 1.25, 2.5 and 5.0 µg) and 
incubated for 30 min at 37 ̊C.  Bound Gpm1p was detected with rabbit 
polyclonal anti-Gpm1p antiserum (1:100) followed by Alexa 647-labeled goat 
anti-rabbit IgG (1:200) and measured using flow cytometer. To know the effect 
of vitronectin on the binding of Gpm1p to human cells, vitronectin (0.1 µg/µl) 
was pre-incubated with biotinylated Gpm1p prior to addition to HUVEC and 
keratinocytes.  Bound Gpm1p was quantified using Streptavidin-conjugated 
Cy5 in flow cytometer. 
Laser scanning microscopy was used to view the binding of Gpm1p to human 
cells.  Confluent host cells grown on 14-mm coverslips in a 24-well tissue 
culture plate were added with 10 mg/ml recombinant Gpm1p in FCS-free 
DMEM and incubated for one hour at 37  ̊C with 5% CO2.  After several 
washes with PBS+1%BSA, rabbit polyclonal anti-Gpm1p antiserum was 
added at a dilution of 1:100 and incubated for 30 min at RT.  Alexa 488-
labeled goat anti-rabbit IgG (1:200) was then added to the wells for 30 min at 
RT.  Wells were washed at least twice between the additions of the two 
antibodies. The coverslips were removed from the wells and viewed using a 
laser scanning microscope. 
 
2.2.4.4. Detection of presence of vitronectin on human cells 
To determine whether HUVEC and keratinocytes endogenously express 
vitronectin, immunological detection of vitronectin was measured using flow 
cytometry and laser scanning microscopy. Steps in Section 2.2.4.3. were 
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followed with the exception of the addition of Gpm1p. To detect vitronectin, 
rabbit polyclonal anti-vitronectin antiserum was used as primary antibody and 
Alexa 488-labeled goat anti-rabbit IgG was used as secondary antibody. 
 
2.2.4.5. Colocalization of Gpm1p and vitronectin on surface of human 
cells 
To observe the colocalization of Gpm1p with the vitronectin on the surface of 
HUVEC and keratinocytes, laser scanning microscopy was used. Gpm1p and 
vitronectin were detected on the surface of human cells by following the 
procedure described in Section 2.2.4.3. with the use of monoclonal Gpm1p 
mouse antibody and polyclonal vitronectin rabbit antiserum. Appropriate 
secondary antibodies used are listed in Table 2. DAPI (4’,6-diamidino-2-
phenylindole) was also added in the antibody mixture to visualize the nucleus 
of the human cells. 
 
2.2.4.6. Measurement of host cell-associated C. albicans or latex beads 
The amount of C. albicans cells or latex beads which associated (adhered 
and endocytosed) with the host cells were measured by flow cytometry and 
viewed using confocal laser scanning microscopy. The host cells were grown 
in 24-well tissue culture plate until confluent.  Prior to inoculation with C. 
albicans yeast cells, host cells were stained with DiO.  After several washes, 
DiD-stained fungal cells (1.0 x 105) were inoculated and the plate was 
incubated for 2 hours at 37  ̊C with 5% CO2. Host cells were removed from the 
wells by using Accutase.  Host cell-associated C. albicans cells were 
measured by determining the amount of host cells with double positive signal 
for DiO and DiD after gating using the forward and sideward scatters. 
To view and measure the amount of Gpm1p-coated blue fluorescent latex 
beads (amine-modified polystyrene, Sigma-Aldrich) which became associated 
with the host cells, indirect immunofluorescence was used.  Gpm1p- or 
biotinylated BSA-coated beads (2.5 x 105) were incubated with confluently-
grown host cells on 14-mm diameter coverslips in 24-well tissue culture plate 
for 45 min at 37  ̊C with 5% CO2.  Coverslips were viewed using a confocal 
laser scanning microscope.  Each coverslip was divided into four quadrants 
where a 5x5 tile scan was done per quadrant.  The mean intensity of the blue 
fluorescence per tile scan was obtained using the ZEN 2009 software. 
 
2.2.4.7. Plasmin(ogen) activity assays 
 
2.2.4.7.1. Chromogenic substrate S-2251 degradation assay 
Plasmin(ogen) activation was determined by hydrolysis of the PL-specific 
substrate S-2251 (D-valyl-leucyl-lysine-ρ-nitroanilide dihydrochloride; 
Haemochrom Diagnostica). To determine functional activity of recombinant 
Tef1p, 10 µg/ml plasminogen was immobilized onto a microtiter plate 
overnight, blocked with 1% bovine serum albumin in DPBS, and plasminogen 
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was activated using 0.08 µg/ml tPa together with the chromogenic substrate 
S-2251 dissolved in reaction buffer (64 mM tris, 350 mM NaCl, 0.01% triton-X; 
pH 7.5). Plasmin activity was recorded at 1 h intervals at 405 nm (SpektraMax 
190; Molecular Devices). 
 
2.2.4.7.2. Fibrinogen and vitronectin degradation assay 
Activity of Tef1p-bound plasminogen was further analyzed by degradation of 
fibrinogen or vitronectin. Ten µg/ml Tef1p was immobilized on microtiter plate 
wells then 20 µg/ml plasminogen, 1 µg/ml tPA, and 20 µg/ml fibrinogen or 
vitronectin were incubated for 2 h at 37°C. Samples were reduced with 
RotiLoad separated by SDS-PAGE, and transferred to a nitrocellulose 
membrane. Fibrinogen degradation fragments were identified using anti-
fibrinogen rabbit antibody (Calbiochem) and secondary goat rabbit antibody, 
while vitronectin degradation products were detected by vitronectin rabbit 
antiserum and HRP-coupled goat rabbit antibody. 
 
2.2.4.7.3. C3b degradation assay 
To characterize the activity of Tef1p-bound plasminogen activity of C3b 
degradation, 20 µg/ml Tef1p was immobilized on microtiter plate wells, then 
20 µg/ml plasminogen was added and incubated for one h at 37°C. Then, 
1 µg/ml tPA, and 10 µg/ml C3b was added after extensive washing. Mixtures 
were incubated for 4 h at 37°C wherein 100 μl samples were collected every 
hour. Samples were reduced with Roti-Load for 5 min at 95°C, separated by 
SDS-PAGE, and transferred onto a nitrocellulose membrane. C3b and their 
cleavage products were detected with anti-C3-Fab-HRP (1:1000).  
 
2.2.4.8. Binding of complement proteins to C. albicans cells 
C. albicans SC5314, tef1 null mutant and reintegration strains were incubated 
with Factor H, C4BP, C3d or plasminogen (10 μg/ml) for 1 h at 37°C. After 
washing twice with DPBS+1% BSA, bound proteins were detected using 
appropriate primary and fluorescent dye-conjugated secondary antibodies 
(Table 2). Antibodies were incubated with C. albicans cells for 30 min at RT 
after fixation with 3% paraformaldehyde. Amount of complement proteins 
which bound to C. albicans cells were quantified using flow cytometry. 
 
2.2.4.9. Reactive oxygen species (ROS) assay 
The ROS assay was performed by Pedro Miramón (Department of Microbial 
Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research, 
HKI). Briefly, neutrophils were seeded at a rate of 5 x 104 cells in each well of 
a microtiter plate which was coated with 0.05% albumin. Cells were incubated 
at 37 °C, 5% CO2, for one hour in phenol red-free RPMI with 4% fetal bovine 
serum. Fifty μl of C. albicans cell suspension with a concentration of 1 x 106 
(MOI=1) was added to each microtiter plate well. Fifty μl of luminol solution (in 
10 ml solution: 20 μl 0.1 M luminol in DMSO, 80 μl horseradish peroxidase, 
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and 9900 μl RPMI without phenol red and FCS) were then added to the 
mixture in each well. Luminescence was immediately measured and 
monitored for one h with a reading every 2.5 min in a fluorescence reader 
(Tecan).  
 
2.2.5. Maintenance and cultivation of human cell lines 
HUVEC cells were maintained in DMEM while HaCaT cells were maintained 
in RPMI 1640. Media were supplemented with 10% fetal calf serum (FCS), 
1% ultraglutamine 1, and 0.055% gentamicin sulfate. Cells were incubated at 
37 °C with 5% CO2. Human cells were passaged every 3 days and only cells 
with less than 30 passages were used in the experiments. 
2.2.6. Statistical analyses 
Standard deviations and significant differences between test groups were 
analyzed by either t-test or analysis of variance (ANOVA) using the software 
GraphPad Prism 6 (GraphPad Software, Inc.)  
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3. RESULTS 
 
3.1. Phosphoglycerate mutase (Gpm1p) 
 
3.1.1. Candida albicans Gpm1p binds to human cells  
The Candida albicans surface protein Gpm1p binds three human innate 
immune proteins, i.e., Factor H, Factor H-like protein 1 and plasminogen. It 
was therefore hypothesized that fungal Gpm1p binds additional human 
proteins and has additional functions, such as binding to human cells. To this 
end, binding of Candida Gpm1p to human cells was analyzed using 
endothelial cells (HUVEC), keratinocytes (HaCaT), and the pre-monocytic cell 
line U937.  Recombinant Gpm1p was added to the human cells and after 
washing, bound Gpm1p was detected with Gpm1p antiserum and quantified 
by flow cytometry. Gpm1p bound to HUVEC and HaCaT but not to U937. 
More Gpm1p bound to HUVEC (MFI=1515) than to HaCat cells (MFI=768) 
(Figure 4A).  In addition, Gpm1p binding to the two human cell lines was 
visualized by confocal laser scanning microscopy (LSM).  Gpm1p bound to 
the surface of HUVEC and HaCaT as revealed by the green fluorescence 
(Figure 4B). Bound Gpm1p was localized to the edge of the individual cells in 
a continuous pattern. Taken together, C. albicans protein Gpm1p binds to 
human endothelial cells and keratinocytes, but not to monocytes. 
 
 3.1.2. Deletion of GPM1 decreases association of C. albicans to human 
endothelial cells  
The role of Gpm1p as a C. albicans surface protein mediating interaction with 
human cell e.g. HUVEC was analyzed using C. albicans SC5314 (wild type), 
GPM1 heterozygous deletion mutant (gpm1Δ), GPM1 homozygous deletion 
mutant (gpm1Δ/Δ), and GPM1 reintegration strain (gpm1Δ/Δ::GPM1).  The 
various C. albicans strains were incubated together with HUVEC cells and 
after washing, the fraction of associated (adhered and/or endocytosed) yeast 
cells was quantified using flow cytometry. GPM1 homozygous deletion mutant 
cells bound less to HUVEC (more than 60% decrease) compared to wild type 
strain (Figure 5). The number of cells of heterozygous mutant and 
reintegration strain which bound to HUVEC was similar as the wild type.  
These results show that Gpm1p mediates adhesion of C. albicans with human 
endothelial cells. 
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FIGURE 4. Candida albicans Gpm1p binds to human cells 
(A) Gpm1p was added to HUVEC, HaCaT or U937. After incubation and subsequent 
washing, bound Gpm1p was detected in flow cytometry using rabbit Gpm1p antiserum 
followed by Alexa Fluor® 647 goat anti-rabbit IgG. Human cells without Gpm1p  were used as 
control. Histograms are representatives of 3 independent experiments. (B) Binding of Gpm1p 
to HUVEC and HaCaT was confirmed by laser scanning microscopy.  HUVEC (top panel) or 
HaCaT (bottom panel) was incubated with Gpm1p, fixed with parafolmaldehyde and after 
washing, bound Gpm1p was detected with rabbit Gpm1p antiserum followed by Alexa Fluor® 
488 goat anti-rabbit IgG (green). DNA of the cells was stained with DAPI (blue). Scale bar = 
10 µm. 
 
 
3.1.3. Association of Gpm1p-coated latex beads to endothelial cells 
To define a direct role of Gpm1p in fungal interaction with human endothelial 
cells, and to eliminate the effect of other fungal surface proteins, attachment 
of Gpm1p-coated latex beads to HUVEC was assessed. Gpm1p was coated 
to blue fluorescent latex beads and the Gpm1p-coated latex beads were 
incubated with HUVEC cells. Bound beads were quantified by measuring their 
blue fluorescence from a specific area of HUVEC by confocal laser scanning 
microscopy. More Gpmp-coated latex beads bound to HUVEC (MFI/μm2=2.5) 
than with latex beads coated with BSA (MFI/μm2=1.6) (Figure 6). Thus, 
Gpm1p is an adhesion protein of the fungal pathogen C. albicans that 
contributes to the adherence to human endothelial cells.  
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FIGURE 5. GPM1 knock-out strain decreases association to endothelial cells. 
Yeast cells of C. albicans SC5314 (wild type), gpm1∆, gpm1∆/∆ or gpm1∆/∆::GPM1 was 
labelled with DiD and incubated with DiO-labelled HUVEC for 120 min at 37 ºC with 5% CO2. 
After washing and detachment, HUVEC with associated (adhered and/or endocytosed) C. 
albicans was identified in flow cytometry as double-positive cells (DiO+, DiD+) by the change 
in side scatter. HUVEC alone detected as single-positive cells (DiO+, DiD-) were used as 
control.  
 
 
 
FIGURE 6.  Association of latex beads with Gpm1p to endothelial cells 
Blue fluorescent latex beads were coated with Gpm1p or biotinylated BSA and incubated with 
HUVEC for 45 min at 37 °C with 5% CO2. HUVEC-associated latex beads were quantified in 
LSM where blue fluorescence was measured per µm2 under the oil immersion objective lens 
using the ZEN 2009 software. Data are mean ± SD (error bars) of three experiments. 
 
 
3.1.4. Candida Gpm1p binds human extracellular matrix protein 
vitronectin 
In order to identify host proteins or ligands for Candida Gpm1p that are 
expressed on the surface of human cells, it was hypothesized that Candida 
Gpm1p would interact with human extracellular matrix components (ECM).  
Therefore, binding of various human ECM proteins to recombinant Gpm1p 
was determined. Immobilized Candida Gpm1p was bound by human 
vitronectin and fibronectin, but not by laminin, fibrinogen, collagen I, collagen 
III, nor collagen IV (Figure 7A).  Since vitronectin showed the most binding to 
Gpm1p, the interaction of the two proteins was analyzed in more detail.  
First, dose-dependent binding of vitronectin to immobilized Gpm1p was 
analyzed using ELISA.  Candida Gpm1p was immobilized and vitronectin (in 
increasing amounts) was added. Bound vitronectin was detected by specific 
vitronectin antiserum. Vitronectin bound to Gpm1p, and binding was dose-
dependent (Figure 7B), indicating the specificity of the interaction. In addition, 
it was determined if heparin-binding regions are involved in the interaction 
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between Gpm1p and vitronectin. To this end, the effect of heparin on 
vitronectin binding to immobilized Gpm1p was determined.  First, heparin was 
added to vitronectin and then the heparin-vitronectin complex was added to 
immobilized Gpm1p. After washing, bound vitronectin was detected in ELISA. 
Heparin inhibited vitronectin binding to immobilized Gpm1p and the effect was 
dose dependent. An approximately 20% decrease in the binding of vitronectin 
to Gpm1p was measured when 0.1 μg heparin was used. Increasing the 
concentration of heparin 10 times (i.e., 1.0 μg) inhibited vitronectin binding to 
Gpm1p by almost 60% (Figure 7C).   
 
 
 
FIGURE 7. Gpm1p binds to human vitronectin 
(A) Vitronectin and fibronectin bind to Gpm1p. Binding of extracellular matrix (ECM) proteins 
to Gpm1p was determined in ELISA. Gpm1p was immobilized on a microtiter plate and added 
with fibronectin, vitronectin, laminin, fibrinogen, collagen I, collagen III, or collagen IV. Bound 
ligand was detected with antiserum specific to each ECM protein followed by HRP-conjugated 
polyclonal IgG specific to the antiserum. Binding of plasminogen to Gpm1p was used as 
control. (B) Vitronectin dose-dependently binds to immobilized Gpm1p. Gpm1p was 
immobilized on a microtiter plate, vitronectin was added in indicated amounts, and bound 
vitronectin was detected by rabbit vitronectin antibody, followed by HRP-conjugated 
polyclonal goat anti-rabbit IgG. (C) Heparin inhibits the binding of vitronectin to Gpm1p. 
Vitronectin and heparin (in indicated amounts) were pre-incubated before adding to 
immobilized Gpm1p. Bound vitronectin was detected as in (B). (D) Interaction of vitronectin 
with Gpm1p is affected by ionic strength. Vitronectin was pre-incubated with NaCl (in 
indicated final concentrations) and added to immobilized Gpm1p. Bound vitronectin was 
detected as in (B). BSA and buffer were used as protein negative and antibody controls, 
respectively. Data are mean ± SD (error bars) of three independent experiments. 
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In addition, the effect of NaCl on the Gpm1p-vitronectin interaction was 
assessed to determine if the interaction is ionic strength-dependent. NaCl at 
the physiological level of 150 mM did not affect vitronectin binding.  However, 
at higher levels of 300 and 600 mM, NaCl reduced the binding of vitronectin to 
Gpm1p by approximately 24% and 38%, respectively, compared to the 
physiological concentration (Figure 7D). Thus, vitronectin binds to Gpm1p via 
heparin-binding sites and the interaction is affected by ionic conditions.   
 
3.1.5. Vitronectin blocks binding of Gpm1p to human cells  
As C. albicans Gpm1p binds to human vitronectin and also to human cells, it 
was hypothesized that vitronectin is one of the major surface ligands for 
Candida Gpm1p on the surface of human cells.  To test this, an assay was 
done to know if vitronectin when added to fluid phase Gpm1p influences or 
blocks Gpm1p binding to human cells.  To this end, vitronectin was added to 
Gpm1p in solution, then the mixture was added to HUVEC or HaCaT cells 
and after washing bound Gpm1p was assayed with appropriate antiserum.  
Vitronectin added to Gpm1p reduced Gpm1p binding to both endothelial cells 
and keratinocytes (Figure 8).  Vitronectin used at 10 μg inhibited Gpm1p 
binding to HUVEC by 91% and keratinocytes by 75%. Thus, vitronectin 
complexed to Gpm1p, blocks binding of the fungal protein to human cells. 
 
 
 
 
FIGURE 8. Vitronectin blocks binding of Gpm1p to human cells 
Biotinylated Gpm1p (10 µg) was pre-incubated with or without vitronectin (10 µg) before 
adding to HUVEC (A) or HaCaT (B). After washing, bound Gpm1p was detected using 
streptavidin-conjugated Cy5 in flow cytometry. Gpm1p when complexed with vitronectin 
(black broken line) showed less binding to human cells than Gpm1p alone (black solid line). 
Human cells without Gpm1p and/or vitronectin was used as control (gray solid line). 
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3.1.6. Vitronectin is present on the surface of human endothelial cells 
and keratinocytes  
Vitronectin is an adhesion cell surface protein of human cells and a regulator 
of the complement system [11,100]. Based on the interaction and the blocking 
effects, it was hypothesized that vitronectin is exposed at the cell surface and 
acts as a ligand for C. albicans Gpm1p.  Therefore, vitronectin expression and 
surface localization on human cells, which were cultivated in serum-free 
medium, was analyzed by flow cytometery using monoclonal vitronectin 
antibody. Significant amount of vitronectin was detected on the surface of 
both HUVEC and HaCaT with an MFI of 2,153 and 819, respectively (Figure 
9A). 
In addition, the surface distribution of vitronectin was visualized by confocal 
microscopy. Vitronectin on cell surface was labelled with polyclonal rabbit 
anti-vitronectin which was then labelled with Alexa 488-conjugated anti-rabbit 
secondary antibody. Human cell membrane was stained with Texas Red-
conjugated wheat germ agglutinin (WGA). Vitronectin (green) was evenly 
distributed on the surface of both HUVEC and keratinocytes which appeared 
in red (Figure 9B). Colocalization of both vitronectin and human cell 
membrane appears in yellow. Taken together, vitronectin is expressed on the 
surface of both HUVEC and HaCaT cells. 
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FIGURE 9. Vitronectin is present on the surface of endothelial cells and keratinocytes. 
HUVEC or HaCaT cells were grown in DMEM or RPMI, respectively, until confluent. After 
washing, human cells were grown in appropriate medium without serum for 24 h. (A) Human 
cells were detached from culture flask and vitronectin expressed on the surface of the cells 
was detected by rabbit vitronectin antibody followed by Alexa Fluor® 647-conjugated goat 
anti-rabbit IgG as secondary antibody. Fluorescence intensity of detected vitronectin is 
represented by solid line. Fluorescence intensity of human cells added only with secondary 
antibody was used as control represented by broken line. (B) Expression of vitronectin by 
human cells was visually confirmed using LSM. Human cells were grown on coverslip in 24-
well plate with appropriate medium until confluent. After washing, human cells were grown in 
serum-free medium without for 24 h. Cells were fixed with 3% paraformaldehyde and after 
extensive washing, vitronectin expressed on the surface of the cells was detected by rabbit 
vitronectin antibody followed by Alexa Fluor® 488-conjugated goat anti-rabbit IgG (green).  
Human cell membrane was also labelled with Texas red-conjugated wheat germ agglutinin 
(red). Scale bar = 20 µm. 
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3.1.7. Candida Gpm1p and vitronectin colocalize at the surface of 
human cells 
In order to prove that vitronectin is the major ligand for Candida Gpm1p on the 
surface of HUVEC and HaCaT, it was determined if Gpm1p and vitronectin 
colocalize at the same sites on human cells using LSM. To this end, Gpm1p 
was bound to the surface of HUVEC or HaCaT cells cultivated in serum-free 
medium. Bound Gpm1p was detected with monoconal Gpm1p antibody while 
bound vitronectin was detected with vitronectin antiserum. Gpm1p (green) 
and vitronectin (red) were detected on the surface of human cells and a 
merge of the two images revealed that the two proteins colocalize at the same 
sites (yellow) (Figure 10).  This indicates that the fungal Gpm1p protein 
specifically binds to vitronectin on the surface of both human endothelial cells 
and keratinocytes. 
 
 
 
 
FIGURE 10. Gpm1p and vitronectin colocalize at the surface of human cells 
Gpm1p (green) is shown to colocalize with vitronectin on the surface of human cells (red) 
using LSM. HUVEC or HaCaT cells in serum-free medium was added with recombinant 
Gpm1p. Human cells with bound Gpm1p were fixed with 3% paraformaldehyde. Gpm1p was 
detected using monoclonal mouse Gpm1p antibody followed by Alexa Fluor® 488-conjugated 
goat anti-mouse IgG. Vitronectin expressed on the surface of the cells was detected by 
polyclonal rabbit vitronectin antibody followed by Alexa Fluor® 647-conjugated goat anti-
rabbit IgG. DNA of human cells was stained with DAPI. Scale bar = 10 µm.  
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3.1.8. Candida albicans uses Gpm1p at the surface to acquire 
vitronectin from human serum 
Vitronectin as an adhesion protein and ECM component is localized at the 
surface of human cells [12]. However, it is also secreted and thereby present 
in soluble form in human plasma at a concentration of ca. 200-400 μg/ml [11]. 
It was therefore asked whether soluble vitronectin in human serum also binds 
the surface-expressed Gpm1p of C. albicans. Binding of vitronectin from 
serum to intact C. albicans cells was first analyzed prior to investigating the 
specific binding of vitronectin to Gpm1p on C. albicans cell surface. To this 
end, yeast cells were incubated in normal human serum (NHS) and cells were 
lyzed after washing. The cell lysate was then separated by SDS-PAGE and 
transferred onto a nitrocellulose membrane. Bound vitronectin was identified 
in Western blot as 65- and 75-kDa bands (Figure 11A). Thus, vitronectin 
derived from human serum binds to the surface of C. albicans. In order to 
prove that Gpm1p on the fungal surface binds soluble Vitronectin, a blocking 
assay was done wherein Gpm1p was first added to hiNHS in order to complex 
soluble vitronectin, then C. albicans cells were incubated in this Gpm1p-
treated hiNHS. After washing, bound vitronectin was detected by a whole-cell 
C. albicans ELISA or by flow cytometry. Less Vitronectin bound to C. albicans 
yeast cells in whole cell ELISA when the yeast cells were incubated in 
Gpm1p-treated hiNHS. The blocking effect was dose-dependent. Ten μg 
Gpm1p were able to effect a 25% decrease in the amount of Vitronectin which 
bound to C. albicans cells (Figure 11B). This blocking effect was also 
confirmed in flow cytometry where C. albicans yeast cells were incubated in 
Gpm1p-treated hiNHS and bound vitronectin was detected by polyclonal 
rabbit anti-Vitronectin and Alexa 647-conjugated anti-rabbit secondary 
antibody. As expected, a decrease in the amount of Vitronectin binding to 
intact yeast cells was measured in samples incubated in Gpm1p-treated 
hiNHS (Figure 11C). An approximately 60% decrease in the bound vitronectin 
was measured when 10 μg of Gpm1p was pre-added to 10% hiNHS. Taken 
together, Gpm1p complexes vitronectin from human serum which then blocks 
binding of the serum protein to C. albicans, implying that Gpm1p is the ligand 
for vitronectin on the surface of C. albicans. 
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FIGURE 11. C. albicans acquires vitronectin from human serum using Gpm1p 
(A) C. albicans binds vitronectin from normal human serum (NHS). C. albicans yeast 
cells were incubated in 10% NHS for 30 min. Following lysis, cell lysate (Lane 1) and 
NHS (Lane 2) was loaded on 10% SDS-PAGE gel, transferred onto a nitrocellulose 
membrane, and vitronectin was detected in Western blot using rabbit vitronectin 
antibody followed by HRP-conjugated goat anti-rabbit IgG. Vitronectin was identified 
as the 75- and 65-kDa bands. The migration of the molecular weight protein 
standards is indicated. (B) Gpm1p decreases the amount of vitronectin which binds 
to C. albicans. The amount of vitronectin from 10% heat-inactivated NHS (hiNHS) 
with or without Gpm1p (in indicated amounts) which bound to immobilized C. 
albicans was measured in whole-cell ELISA. Bound vitronectin was detected by 
HRP-conjugated goat anti-rabbit IgG. C. albicans cells without hiNHS and Gpm1p 
were used as antibody control. Data are mean ± SD (error bars) of three independent 
experiments. (C) The inhibition of the binding of vitronectin (from hiNHS) to C. 
albicans by Gpm1p was also confirmed in flow cytometry. C. albicans yeast cells 
were incubated in hiNHS with or without Gpm1p (0 µg, dotted line; 1 µg, broken line; 
10 µg, black solid line). Bound vitronectin was detected by the same primary 
antibody as in B but with Alexa Fluor® 647-conjugated goat anti-rabbit IgG as 
secondary antibody. C. albicans cells without hiNHS and Gpm1p were used as 
control. Histograms are representatives of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 43 
3.2. Translation elongation factor 1-alpha (Tef1p) 
 
3.2.1. Cloning and recombinant expression of C. albicans Tef1p 
Screening for Factor H-binding proteins of C. albicans led to the identification 
of translation elongation factor 1-alpha (Tef1p) (data not shown). To confirm 
and characterize the binding of Candida Tef1p to the human plasma protein 
Factor H, a recombinant Tef1p protein was produced using E. coli.  The TEF1 
gene (orf19.1435) was amplified from the genomic DNA isolated from C. 
albicans SC5314 and subcloned into the pET101 expression vector producing 
pET101-CaTef1. The plasmid pET101-CaTef1 was designed to have histidine 
tag at the C-terminus of TEF1 for purification of the recombinant protein later 
on. After confirmation of the right insertion of the gene into the vector by 
sequencing, pET101-CaTef1 was transformed into the E. coli expression 
strain BL21 Star (DE3). Expression of the recombinant Tef1p was induced by 
IPTG and expression rate was monitored for 6 hours. After cultivation, E. coli 
cells were lyzed and lysate supernatant was collected and separated in SDS-
PAGE. The presence of Tef1p in the cell lysate supernatant was detected in 
Western blot using monoclonal penta-His antibody. A 55-kDa band was 
identified in the lysate supernatant of IPTG-induced culture (Figure 12A) but 
not in non-induced culture (Figure 12B). Expression of Tef1p started after 
one hour of incubation (Figure 12A, Lane 2). In addition, the pellet from 
IPTG-induced cell lysate was also collected and analyzed for the presence of 
Tef1p as described above. A more prominent Tef1p band was detected in the 
pellet (Figure 9B, Lanes 2 and 4) compared to the supernatant (Figure 9B, 
Lanes 1 and 3), which implied that the recombinant protein was insoluble.   
To solubilize the insoluble recombinant Tef1p, a protocol for purification and 
refolding of His-tagged insoluble recombinant protein produced in E. coli from 
Amersham Biosciences (citation) was used together with the guidelines in the 
user manual of the Champion pET Directional TOPO Expression Kits by 
Invitrogen. The procedure included the solubilization of the protein obtained in 
the pellet of the cell lysate, denaturation, purification by running through Äkta 
purification system via the His-tag, in-column refolding and elution (Figure 
12D). The elute fractions were pooled, desalted and concentrated by 
ultracentrifugation. The wash fractions were also collected during desalting to 
make sure that no proteins were washed away during the washing process.  
The concentrated Tef1p sample showed a single prominent band in both 
silver stained gel and Western blot with molecular mass of 55 kDa (Figure 
12E).  
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FIGURE 12. Expression and purification of recombinant Tef1p 
Test expression of His-tagged Tef1p in the BL21 Star™(DE3) E. coli strain harboring the 
pET101-CaTef1 plasmid was done by incubating cells in LB broth with (A) or without IPTG (1 
mM) (B) for 6 h at 37 ºC. Ampicillin (100 µg/ml) was added in the medium as selection 
marker. Culture supernatants were taken every hour and were loaded on 10% SDS-PAGE 
gels. Gels were silver stained or transferred onto a nitrocellulose membrane for Tef1p 
detection in Western blot using monoclonal anti-penta-His IgG.  
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FIGURE 12. Expression and purification of recombinant Tef1p (continued) 
(E) Tef1p was eluted from Äkta protein purification system (Lanes 1 and 3), desalted and 
washed twice with DPBS (Lanes 2-3 and 4-5), and concentrated in ultracentrifuge filters 
(Lanes 4 and 6). Samples were taken from each step and loaded on 10% SDS-PAGE gel for 
silver staining (Lanes 1-4) or Western blotting using monoclonal anti-penta-His IgG to detect 
his-tagged Tef1p. The migration of the molecular weight protein standards is indicated. (C) 
Recombinant Tef1p is produced as insoluble inclusion bodies in E. coli cell lysate pellet.  E. 
coli cells were cultured in IPTG-induced LB broth with ampicillin for  4 h  at 37 ºC. After cell 
lysis and subsequent centrifugation, supernatant (Lanes 1 and 3) and pellet  (Lanes 2 and 4) 
were collected and loaded on 10% SDS-PAGE gel. Gel was silver-stained (Lanes 1 and 2) or 
transferred onto nitrocellulose membrane for Tef1p detection in Western blot using 
monoclonal anti-penta-His IgG (Lanes 3 and 4). (D) Schematic diagram of the workflow for 
isolation, denaturation, purification, folding and elution of recombinant Tef1p. 
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3.2.2. Candida Tef1p binds human complement proteins 
To confirm that Candida Tef1p binds to Factor H, an enzyme-linked 
immunosorbent assay (ELISA) was used. Tef1p was immobilized and Factor 
H was added in increasing amounts. Bound Factor H was detected by anti-
Factor H goat polyclonal antiserum. Factor H bound to immobilized Tef1p and 
binding was dose-dependent (Figure 13A). 
 
 
 
 
FIGURE 13. Components of the human complement system bind to Tef1p 
Binding of components of the human complement system to Tef1p was assayed in ELISA. 
Tef1p was immobilized on microtiter plate. Factor H (A), C4BP (B), C3d (C), or C3dg (D) was 
added at indicated concentrations. After washing, bound ligand was quantified using ligand-
specific antiserum: goat Factor H antiserum for A, rabbit C4BP antiserum for B, and rabbit 
C3d antiserum for C and D. The primary antibody was followed by HRP-conjugated rabbit 
anti-goat IgG (for A) or goat anti-rabbit IgG (for B, C, and D). (E) Factor H binds to Tef1p-
bound C3d forming a tripartite complex. Tef1p was immobilized on microtiter plate and added 
with C3d at indicated concentrations. After washing, Factor H was added and bound Factor H 
was detected by goat Factor H antiserum followed by HRP-conjugated rabbit anti-goat IgG. 
The staphylococcal Efb was used as postivie control for C3d (D) and C3dg (D). HSA was 
used as negative control for A, B and E while BSA was used for C and D. Buffer was used as 
antibody control. Data are mean ± SD (error bars) of three independent experiments. 
 
 
To test if Candida Tef1p also binds the human complement regulator C4BP, 
Tef1p was immobilized and C4BP was added in increasing amounts. Bound 
C4BP was detected in ELISA by anti-C4BP rabbit polyclonal antiserum. C4BP 
bound to immobilized Tef1p and binding was dose dependent (Figure 13B). 
C3b degradation product C3d was shown to bind to the surface of C. albicans 
and was speculated to help the fungus evade phagocytosis by mediating the 
clumping of hyphal cells [115]. To determine whether Tef1p interacts with C3d 
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and C3dg, an ELISA was performed where Tef1p was immobilized and C3d 
or C3dg binding was studied. C3d or C3dg was added in increasing amounts. 
At the same time, a positive control wherein staphylococcal extracellular 
fibrinogen-binding protein (Efb), a known C3d ligand from the bacterium 
Staphylococcus aureus, was also immobilized and added with increasing 
amounts of C3d or C3dg. Bound C3d or C3dg was detected by rabbit 
polyclonal C3d antiserum. C3d bound to Tef1p and the binding was dose-
dependent (Figure 13C).  However, more C3d bound to staphylococcal Efb 
than to Tef1p. Approximately 44% more C3d bound to Efb than to Tef1p at a 
C3d concentration of 5.0 µg/ml. C3d did not bind to immobilized BSA, which 
was used as negative control. The C3b degradation product C3dg also bound 
to immobilized Tef1p and the binding was dose-dependent (Figure 13D). 
Twenty-two percent more C3dg bound to Efb than to Tef1p at 0.5 µg/ml C3dg 
concentration.  
To further confirm the specificity of the Tef1p-C3d interaction, the amount of 
Factor H which bound to Tef1p-complexed C3d was measured in ELISA. At 
first, C3d, in increasing amounts, was added to immobilized Tef1p. Then, 
Factor H was added in constant amount to Tef1p-complexed C3d after 
extensive washing. Bound Factor H was detected by goat polyclonal anti-
Factor H antibody. Factor H bound to Tef1p-complexed C3d and the binding 
was dose-dependent. This confirms that C3d specifically binds to Candida 
Tef1p and can mediate the generation of a tripartite complex between Tef1p, 
C3d and Factor H (Figure 13E). Taken together, this demonstrates that 
Candida Tef1p binds the complement regulators Factor H and C4BP, and the 
C3b degradation products C3d and C3dg. 
 
3.2.3. Candida Tef1p binds plasminogen  
Tef1p was identified to be one of the surface proteins of C. albicans which 
bind the plasma protein plasminogen [9,37]. To confirm the binding of 
plasminogen to Candida Tef1p, Tef1p was immobilized and plasminogen was 
added in increasing amounts. Bound plasminogen was detected using goat 
polyclonal anti-plasminogen in ELISA. Plasminogen bound to Tef1p and the 
binding was dose-dependent (Figure 14A). The Tef1p-plasminogen 
interaction was further confirmed with the use of surface plasmon resonance 
(SPR). Plasminogen was applied as analyte and association to immoblized 
Tef1p was measured. Plasminogen, at concentrations of 100-400 nM, bound 
to Tef1p in a dose dependent manner (Figure 14B). The Tef1p-plasminogen 
complex was stable and had a slow dissociation profile. 
Plasminogen interaction with other C. albicans surface proteins such as 
Gpm1p and Pra1 are known to involve lysine residues [61,62,116]. To 
determine if this is also the case for Tef1p, the lysine analog ε-aminocaproic 
acid (ε-ACA) was used in an inhibition assay using ELISA. Plasminogen was 
incubated with ε-ACA in increasing amounts and added to immoblized Tef1p. 
Bound plasminogen was detected using the goat polyclonal anti-plasminogen 
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antibody. ε-ACA inhibited plasminogen binding to Tef1p and the inhibition was 
dose-dependent (Figure 14C). ε-ACA inhibited 58% of the binding at 0.4 mM 
concentration. However, the same inhibition level was reached even with the 
use of 1.0 mM ε-ACA. The ε-ACA-mediated inhibition of Tef1p-plasminogen 
interaction was confirmed in SPR analysis. Plasminogen, preincubated with ε-
ACA in increasing amounts, was used as analyte and association with 
immobilized Tef1p was measured. As expected, ε-ACA inhibited plasminogen 
binding to Tef1p and the inhibition was dose-dependent. ε-ACA, at a 
concentration of 2.0 nM could totally abolish the interaction between 
plasminogen and Tef1p (Figure 14D). Thus, lysine residues are involved in 
the interaction between Tef1p and plasminogen. 
 
FIGURE 14. Plasminogen binds to Tef1p 
Plasminogen binds to Tef1p in a dose-dependent manner. Binding of plasminogen to Tef1p 
was  assayed in ELISA (A). Tef1p was immobilized on microtiter plate and plasminogen was 
added at indicated concentrations. Bound plasminogen was detected by goat plasminogen 
antiserum and HRP-conjugated rabbit anti-goat IgG. The dose-dependent binding of 
plasminogen to Tef1p was confirmed by surface plasmon resonance (SPR) analysis (B). 
Tef1p was immobilized on the chip surface, and plasminogen was used as the analyte in fluid 
phase at indicated concentrations.  Lysine residues are involved in the interaction between 
Tef1p and plasminogen. The effect of the lysine analog ε-ACA on plasminogen binding to 
Tef1p was assayed in ELISA (C). Plasminogen with ε-ACA (in indicated concentrations) was 
added to immobilized Tef1p on microtiter plate. Bound plasminogen was detected as in A. ε-
ACA reduced the binding of plasminogen to Tef1p in a dose-dependent manner. The effect of 
ε-ACA on plasminogen binding to Tef1p was confirmed in SPR analysis (D). Tef1p was 
immobilized on the chip surface, and plasminogen with ε-ACA (in indicated concentrations) 
were applied in the fluid phase as analyte. HSA was used as negative protein control for A 
and C. Buffer was used as antibody control. Data of A and C are mean ± SD (error bars) of 
three independent experiments. Data of B and D are representatives of 3 independent 
experiments. 
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3.2.4. Tef1p-bound plasminogen is converted to functionally active 
plasmin 
Plasmin is a protease that degrades fibrinogen, ECM proteins and the 
complement component C3b [9]. To determine if an active plasmin is 
generated from Tef1p-bound plasminogen, degradation of different substrates 
was determined in a series of plasminogen activation assays. To this end, 
plasminogen was bound to immobilized Tef1p, and after extensive washing, 
the tissue-type plasminogen activator (tPA) was added together with the 
substrate (chromogenic S-2251, fibrinogen, vitronectin, or the complement 
component C3b). Following incubation, degradation of substrate was 
monitored in a time-dependent manner. Tef1p-bound plasminogen could be 
activated to plasmin and degrade the synthetic substrate S-2251. An 
exponential change in absorbance, which is proportional to plasmin activity 
that produces chromogenic degradation product, was observed for almost 15 
h before the degradation profile started to remain constant at Absorbance450 
nm = 1.2 (Figure 15A). The fluid-phase plasminogen could be activated to 
plasmin in a faster rate where the S-2251 substrate was readily degraded in 
the first 4 h before reaching a constant Absorbance450 nm = 1.0. The negative 
control HSA did not bind plasminogen, so no change in absorbance was 
observed. Also, no change in absorbance was measured in samples lacking 
plasminogen or tPA in the reaction mixture. 
The degradation activity of Tef1p-bound plasminogen was also assayed using 
its natural substrates fibrinogen and vitronectin. To this end, plasminogen was 
bound to immobilized Tef1p and after extensive washing, tPA and the 
substrate fibrinogen or vitronectin were added. After incubation, the proteins 
in the reaction mixture were separated in SDS-PAGE, transferred onto a 
membrane, and fibrinogen or vitronectin was detected by Western blotting. 
Tef1p-bound plasminogen, when activated to plasmin, degraded fibrinogen 
(Figure 15B). Cleavage of both 55- and 72-kDa fibrinogen bands was seen 
after two hours. The positive control plasminogen when activated with tPa in 
fluid phase completely degraded fibrinogen, as evidenced by the 
disappearance of the fibrinogen bands (Figure 15B, Lane 4). 
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FIGURE 15. Plasminogen bound to Tef1p is functionally active 
(A) Plasminogen was bound to Tef1p that was immobilized on microtiter plate. After extensive 
washing, the activator tPA (4 ng/well) together with chromogenic substrate S-2251 were 
added, and the rate of product formation was monitored for 24 h by absorbance at 405 nm. 
The rate of product formation is proportional to the activity of plasmin(ogen). Assay performed 
with fluid-phase plasminogen was used as positive control while plasminogen added to 
immobilized HSA was used as negative control. Degradation activity of Tef1p-bound 
plasmin(ogen) was done in an assay using the natural substrates fibrinogen (B) and 
vitronectin (C). Plasminogen (was bound to immobilized Tef1p and after washing, tPA 
together with the substrate were added (B and C, Lane 1). Samples were collected after two 
hours, loaded on 10% SDS-PAGE gel, transferred onto a nitrocellulose membrane, and 
degradation was determined by Western blotting using rabbit fibrinogen (B) or vitronectin (C) 
antiserum. Plasminogen in fluid phase added with tPA was used as positive control (B and C, 
Lane 4). Assays performed in the absence of plasminogen (B and C, Lane 2) or tPA (B and 
C, Lane 3) were used as negative controls. Molecular weights of degradation products are 
indicated. 
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Tef1p-bound plasminogen, when activated to plasmin, also degraded 
vitronectin (Figure 15C). Vitronectin degradation was identified by the 
disappearance of the 75-kDa  band and the appearance of approximately 30-
kDa degradation product. The positive control plasminogen when activated 
with tPa in fluid phase completely degraded vitronectin as evidenced by the 
disappearance of both the 65- and 75-kDa vitronectin bands (Figure 15C, 
Lane 4). The lack of tPa (Figures 15B and 15C, Lane 2) or plasminogen 
(Figures 15B and 15C, Lane 3) did not degrade the substrates as 
demonstrated by the intact protein bands. Overall, plasminogen when bound 
to Tef1p, can be activated to the protease plasmin and maintain its 
degradation activity. 
 
3.2.5. Tef1p-bound plasminogen cleaves the complement component 
C3b 
It was recently shown that plasminogen degrades the complement component 
C3b [9]. To determine if the Tef1p-bound plasminogen degrades C3b, first, 
plasminogen was bound to immobilized Tef1p and after washing, tPA and 
C3b were added. Next, samples were collected at specific intervals for 4 
hours. C3b cleavage was determined in Western blot by the appearance of 
the cleavage products α΄43- and α’41-kDa bands. The Tef1p-bound 
plasminogen cleaved C3b in a time-dependent manner with the appearance 
of the early cleavage products after two hours (Figure 16A, Lane 2). C3b 
cleavage products increased after 3 and 4 hours (Figure 16B, Lanes 3 and 
4) as seen in the significant increase in the intensities of the cleavage product 
bands. The appearance of C3b cleavage products in the blot where the assay 
was performed in fluid phase was used as reference (Figure 16B). No C3b 
cleavage products were seen in samples without plasminogen, tPA or Tef1p 
(Figure 16C; Lanes 1, 2 and 3, respectively). Taken together, Tef1p-bound 
plasminogen is activated to plasmin and cleaves C3b. 
 
 
 
 
Results 
 52 
FIGURE 16. Tef1p-bound plasminogen cleaves the complement component C3b 
Plasminogen was added to immobilized Tef1p on microtiter plate. After extensive washing, 
the activator tPA (4 ng/well) and the substrate C3b (5 µg/ml) were added. Samples from the 
reaction mixture were collected at indicated times, separated by SDS-PAGE, transferred onto 
a nitrocellulose membrane, and C3b cleavage products were identified in Western blot using 
goat C3 antiserum and HRP-conjugated rabbit anti-goat IgG. C3b is identified by the α’-chain 
and the β-chain. C3b degradation is visualized by the appearance of the cleavage products 
as α’68, α’43, and α’41 fragments (A and B, Lanes 2-4). Degradation of C3b by activated fluid 
phase plasminogen was used as positive control (B). Reaction mixtures without plasminogen 
(C, Lane 1), tPA (C, Lane 2) or Tef1p (C, Lane 3) were used as negative controls. 
 
 
3.2.5. Tef1p is expressed on the surface of C. albicans 
For Candida Tef1p to bind Factor H and plasminogen, it must be secreted 
and/or present on the fungal cell surface. To determine the Tef1p expression 
on the surface of C. albicans, Tef1p-specific antiserum was first generated 
against Tef1p by immunizing rabbits with the purified recombinant Tef1p. The 
generated rabbit Tef1p antiserum detected the recombinant protein in 
Western blot as 55-kDa band in Western blot (Figure 17A, Lane 1). The 
same band was detected by the mouse monoclonal antibody reacting with 
penta-His (Figure 17A, Lane 3). The Tef1p band was not detected with pre-
immune serum (Figure 17A, Lane 2). 
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FIGURE 17. Tef1p is expressed on the surface of C. albicans 
Tef1p antiserum (α-Tef1p) was generated in rabbit using recombinant Tef1p. (A) 
Recombinant Tef1p was loaded on SDS-PAGE gel and transferred onto nitrocellulose 
membrane for detection in Western blotting using rabbit pre-immune serum (Lane 2), rabbit 
Tef1p antiserum (Lane 1) or monoclonal mouse penta-His IgG (α-penta-His) (Lane 3). Rabbit 
pre-immune serum or Tef1p antiserum was detected by HRP-conjugated goat anti-rabbit IgG. 
α-penta-His was detected by HRP-conjugated goat anti-mouse IgG. (B) C. albicans cell wall 
(Lane 1) and cytoplasm (Lane 2) fractions were loaded on SDS-PAGE, transferred onto 
nitrocellulose membrane and analyzed by Western blotting for the presence of native Tef1p 
using α-Tef1p and HRP-conjugated goat anti-rabbit IgG. The migration of the molecular 
weight protein standards and the Tef1p band are indicated. (C) Tef1p is present on yeast and 
hyphal cells of C. albicans. Yeast or hyphal cells were incubated with α-Tef1p or pre-immune 
serum, followed by Alexa Fluor® 647-conjugated goat anti-rabbit IgG, and fluorescence was 
measured by flow cytometry.  
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FIGURE 17. Tef1p is expressed on the surface of C. albicans (continued) 
(D) Expression of Tef1p on surface of C. albicans was visually confirmed in LSM. GFP-
expressing yeast (top panel) or hyphal (bottom panel) cells (green) were attached onto a 
coverslip and fixed with 3% parafolmaldehyde. After washing, cells were incubated with α-
Tef1p and Alexa Fluor® 647-conjugated goat anti-rabbit IgG (red). Scale bar = 10 µm (top 
panel) or 20 µm (bottom panel). 
 
 
The Tef1p native form was detected in samples from cell wall and cytoplasm 
of C. albicans SC5314 using the generated Tef1p antiserum in Western blot. 
Tef1p was detected in both cell wall and cytoplasm as a 55-kDa band along 
with several other bands (Figure 17B). The other bands with less than 55-
kDa molecular mass could be Tef1p degradation products while the bands 
with more than 55-kDa molecular mass could be Tef1p complexed with other 
cellular proteins (Figure 17B, Lanes 1 and 2). 
Aside from confirming the cellular localization of Tef1p, we also compared the 
expression of the protein on the surface of yeast and hyphae forms of C. 
albicans. The surface expression of Tef1p in both cellular forms was 
measured by flow cytometry and visually confirmed by laser scanning 
microscopy using the rabbit Tef1p antiserum. Yeast and hyphal cells 
expressed Tef1p on their surfaces. However, more Tef1p was detected on the 
surface of hyphal cells (MFI=513) than yeast cells (MFI=16) (Figure 17C). 
Visually, Tef1p expression on yeast cells was seen only at the budding part of 
the cells (Figure 17D, top panel), whereas the Tef1p expression on hyphal 
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cells was observed all throughout the surface of the hyphae (Figure 17B, 
bottom panel) indicating that Tef1p is mainly expressed on hyphal form of 
the fungus. 
 
3.2.6. Generation of C. albicans TEF1 knock-out and revertant strains 
To determine the role of Tef1p on the binding of C. albicans to proteins of the 
innate immune system, tef1Δ/Δ deletion mutant strain was generated using 
the PCR-based gene disruption technique [116,117]. Strains BWP17 (wild-
type), tef1Δ heterozygous deletion mutant, and tef1Δ/Δ homozygous deletion 
mutant were genetically analyzed for the correct deletion of TEF1 by PCR and 
Southern blot analyses. For the PCR analysis, two sets of primers were used 
to specifically amplify TEF1. The first primer pair amplified the region between 
the upstream flanking region (TEF1-disrptnup) and middle of the TEF1 gene 
sequence (TEF1_2) while the other pair amplified the region from the middle 
of the TEF1 gene sequence (TEF1_3) and downstream flanking region 
(TEF1-disrptndown). The expected PCR product sizes of 927 bp and 924 bp 
were seen in WT and tef1Δ but not in tef1Δ/Δ (Figure 18A), indicating the 
deletion of the TEF1 gene in the tef1Δ/Δ deletion mutant. 
Confirmation of TEF1 deletion was done using Southern blotting, wherein 517 
base-pair (bp) PCR product amplified by the primers CaTEF1Int-Fwd and 
CaTEF1Int-Rev from C. albicans SC5314 genomic DNA, was used as a probe 
on PciI-digested genomic DNA (Figure 18B). The expected size of 6282 bp 
was detected in WT and tef1Δ, with the latter having only a faint band since it 
only had one copy of the TEF1 gene (Figure 18C). No band was seen in 
tef1Δ/Δ at the expected size. However, since the TEF2 gene shares 99% 
identity with TEF1, another band was detected at the size of 2218 bp in all 
samples.  Overall, the TEF1 gene was successfully deleted in C. albicans. 
To obtain the tef1Δ/Δ::TEF1-reintegration strain, CIp10-TEF1 plasmid was 
used to transform the uridine auxotrophic C. albicans strain tef1Δ/Δura-. 
Integration of the plasmid was confirmed in PCR by amplifying the region 
between URA3 and the flanking region of RP10 locus using the primers 
URA3-F2 and RPF-F1. A PCR product was seen in the TEF1 reintegration 
strain while no band was seen in the tef1Δ/Δ deletion mutant, indicating the 
successful reintegration of TEF1 (Figure 18D). 
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FIGURE 18. Generation of C. albicans TEF1 knock-out and revertant strains. 
(A) Successful deletion of both gene copies of TEF1 was determined by PCR using primers 
which amplify the region between upstream flanking region and middle of ORF or middle of 
ORF and downstream flanking region of TEF1 (orf19.1435). The gene sequences were 
amplified in wild type (Lanes 3 and 6) and tef1∆ heterozygous deletion mutant (Lanes 2 and 
5) but not in tef1∆/∆  homozygous deletion mutant (Lanes 1 and 4). The sizes of the amplified 
gene products are indicated. (B) Schematic representation of the Southern blotting strategy 
used to confirm the deletion of TEF1 in tef1∆/∆. A 517-bp probe was amplified from genomic 
DNA of C. albicans SC5314. The probe was used on PciI-digested genomic DNA. The 
expected band sizes are indicated for TEF1 and TEF2, which shares 99% identity with TEF1. 
(C) Southern blot confirming the deletion of TEF1. Strains tef1∆/∆ (Lane 1), tef1∆ (Lane 2) 
and SC5314 (wild type, Lane 3) were analyzed. Sizes of detected TEF1 and TEF2 are 
indicated. (D) Confirmation of the reintegration of TEF1 using PCR. The correct reintegration 
of TEF1 in RP10 locus of the genomic DNA of tef1∆/∆::TEF1 reintegration strain and tef1∆/∆ 
deletion mutant was determined by amplifying the region between URA3 and RP10 locus 
flanking region. 
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3.2.7. Characterization of C. albicans TEF1 knock-out mutant  
Translation elongation factor 1-alpha is possibly an essential gene in C. 
albicans [87]. To determine if deletion of TEF1 affects the viability of C. 
albicans, the tef1Δ/Δ deletion mutant was grown in liquid or on solid YPD 
medium and the growth was monitored at different incubation conditions. The 
tef1Δ/Δ deletion mutant grew in YPD broth after 14 h at 30 °C at the same 
rate as the wild type and the tef1Δ/Δ::TEF1-reintegration strain (Figure 19A). 
In addition, tef1Δ/Δ deletion mutant grew on YPD agar at 30 °C and 37 °C 
after 72 h of incubation in the same manner as the wild type and revertant 
strain (Figure 19B). Taken together, deletion of TEF1 in C. albicans does not 
affect the growth of the fungus, indicating that TEF1 is a non-essential gene. 
Since Tef1p is expressed on the surface of C. albicans, the effect of various 
cell wall disturbing agents and stresses on the growth of tef1Δ/Δ deletion 
mutant was investigated. The cell wall perturbing agents calcofluor white (7 
nM), congo red (20 µg/ml), and SDS (0.004%) did not affect growth of tef1Δ/Δ 
deletion mutant in YPD at 30 °C for 72 h (Figure 19C). In the same manner, 
the tef1Δ/Δ mutant had the same growth as the wild type and tef1Δ/Δ::TEF1-
reintegration strain in NaCl (1.5 M) and D-sorbitol (1.0 M), indicating that 
TEF1 is not necessary in osmotic stress resistance of C. albicans (Figure 
19D). The oxidative stressors menadione (25 µM), H2O2 (2.0 mM), and t-butyl 
hydroperoxide (t-BOOH, 2.0 mM) had no effect on the growth of tef1Δ/Δ 
deletion mutant (Figure 19E). In conclusion, deletion of TEF1 does not affect 
the cell wall integrity of C. albicans and its adaptation to osmotic and oxidative 
stress. However, deletion of TEF1 made C. albicans sensitive to the 
antifungal hygromycin B (0.5 mg/ml) and reintegration of TEF1 in tef1Δ/Δ 
deletion mutant restored the growth (Figure 19F). Thus, TEF1 contributes to 
the resistance of C. albicans against an antibiotic whose mode of action is to 
inhibit protein synthesis. 
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FIGURE 19. Characterization of TEF1 homozygous deletion mutant 
Growth rate of C. albicans SC5314 (wild type), tef1∆/∆ deletion mutant, and tef1∆/∆::TEF1 
reintegration mutant in YPD broth at 30 ºC was monitored for 14 h by collecting samples 
every hour and measuring the optical density (OD) at 600 nm. (B) Ten-fold serial dilutions of 
C. albicans SC5314 (wild type), tef1∆/∆, and tef1∆/∆::TEF1 were spotted on YPD agar and 
incubated for 2-3 days at 30 ºC or 37 ºC. Growth of strains under different environmental 
stresses was determined in spot test analysis. Ten-fold serial dilutions of wild type, tef1∆/∆, 
and tef1∆/∆::TEF1 were spotted on YPD agar  with different stress conditions including (C) 
cell wall stress [calcofluor white (6.7 nM), congo red (20 µg/ml), and SDS (0.004%)], (D) 
osmotic stress [NaCl (1.5 M) and sorbitol (1.0 M)], and (E) oxidatve stress [menadione (25 
µM), H2O2 (2 µM), and t-BOOH (2 mM)]; and (F) antifungal hygromycin (0.5 mg/ml). Plates 
were incubated for 2-3 days at 30 ºC. Experiments were repeated at least twice yielding 
similar results. Representative pictures are shown. 
 
3.2.8. Deletion of TEF1 decreases binding of plasminogen and C3d on 
C. albicans 
Because Tef1p binds components of the complement system, the effect of the 
deletion of TEF1 on the binding of Factor H, C4BP, C3d and plasminogen by 
C. albicans was analyzed. To this end, purified Factor H, C4BP, C3b or 
plasminogen was bound to the tef1Δ/Δ deletion mutant, and bound proteins 
were detected with appropriate antisera in flow cytometry. Factor H bound 
tef1 deletion mutant in the same manner as the wild type and tef1Δ/Δ::TEF1-
reintegration strain (data not shown). In addition, the same amount of C4BP 
bound to tef1Δ/Δ deletion mutant compared to the wild type and 
tef1Δ/Δ::TEF1-reintegration strain (data not shown).  
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FIGURE 20. Deletion of TEF1 decreases binding of plasminogen and C3d to C. albicans 
Binding of plasminogen (A) or C3d (B) to wild type, tef1Δ/Δ deletion mutant, and 
tef1Δ/Δ::TEF1 reintegration strain was determined by flow cytometry. Yeast cells were 
incubated with plasminogen or C3d. Bound plasminogen was detected by goat plasminogen 
antiserum followed by Alexa Fluor® 647-conjugated rabbit anti-goat IgG. Bound C3d was 
detected by rabbit C3d antiserum followed by Alexa Fluor® 647-conjugated goat anti-rabbit 
IgG. Data are reported as % difference from antibody control. Bars are representatives of 3 
independent experiments. 
 
 
However, plasminogen and C3d bound less to the tef1 knock-out strain. The 
tef1Δ/Δ deletion mutant bound 67.5% less plasminogen in comparison to the 
wild type, and 71.9% less in comparison to the tef1Δ/Δ::TEF1 reintegration 
strain (Figure 20A). In addition, tef1Δ/Δ deletion mutant bound 92.6% and 
87% less C3d than the wild type and tef1Δ/Δ::TEF1 reintegration strain, 
respectively (Figure 20B). Taken together, deletion of TEF1 decreases the 
ability of C. albicans to bind the plasma protein plasminogen and complement 
component C3d but not Factor H and C4BP. 
 
3.2.9. C. albicans Tef1p interacts with human neutrophils 
Neutrophils, as central components of the innate immune system, directly 
attack C. albicans [28]. To determine the role of Tef1p on the interaction of C. 
albicans with human neutrophils, Tef1p was added to neutrophils and bound 
Tef1p was measured using flow cytometry. Tef1p bound to freshly isolated 
human neutrophils with an MFI of 467.8 compared to the antibody control with 
an MFI of 167.1 (Figure 21A). Thus, Candida Tef1p binds to human 
neutrophils.  
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FIGURE 21. C. albicans Tef1p interacts with neutrophils 
Tef1p binds to neutrophils. Tef1p (10 µg) was incubated with freshly-isolated PMNs from 
human peripheral blood. Bound Tef1p was quantified using rabbit Tef1p antiserum and Alexa 
Fluor® 647-conjugated goat anti-rabbit IgG in flow cytometry. Cells were incubated with Fc 
receptor blocker prior to addition of primary antibody. Cells without Tef1p were used as 
control. (B) Deletion of TEF1 in C. albicans reduces the reactive oxygen species (ROS) 
response by PMNs. ROS release by PMNs incubated with C. albicans strains was measured 
using luminol-based chemiluminescence. C. albicans SC5314 (wild type), tef1∆/∆ deletion 
mutant, or tef1∆/∆::TEF1 reintegration strain was added to neutrophils at MOI=1 and 
incubated at 37 ºC with 5% CO2, recording the chemiluminescence every 2.5 min for 2.5 h. 
PMNs incubated with or without phorbol 12-myristate 13-acetate (PMA) was used as positive 
or negative control, respectively. Data are reported as mean of areas under the curve in 
relative luminiscence units (RLU). Error bars represent SD of three independent experiments. 
*P<0.01 compared with the wild type strain. 
 
Release of reactive oxygen species (ROS) by human neutrophils is an 
effector mechanism to directly kill invading microorganisms [34,117]. Because 
Tef1p binds to neutrophils, and as fungal surface proteins contribute to the 
interaction between C. albicans and neutrophils, the amount of released ROS 
induced by C. albicans tef1 knock-out strain was measured with the use of 
luminol-based chemiluminescence. A significantly reduced amount of ROS 
released by the human neutrophils was induced by the C. albicans tef1 knock 
out strain. When tef1Δ/Δ deletion mutant was cocultivated with neutrophils, 
the neutrophils released 29% less ROS in comparison to the wild type and 
8.7% less than that of tef1Δ/Δ::TEF1-reintegration strain (Figure 21B). This 
suggests that Tef1p contributes the recognition of C. albicans by neutrophils 
or induces a specific receptor on the surface of neutrophils which activates 
the release of ROS. 
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4. DISCUSSION 
 
Host-pathogen interactions are governed by several mechanisms in which 
both players try to maintain a balance to co-exist. On the one hand, microbial 
pathogens have evolved a plethora of strategies to survive in its chosen niche 
inside the human body. On the other hand, the human host has developed 
itself with various means to counteract the undesirable effects of the foreign 
microbial pathogens. However, when one of the players gets compromised, 
the other dominates and causes destructive consequences. Such is the case 
when the human body acquires a defect in its machineries to control growth of 
fungal pathogens, like neutropenia. In this situation, fungal pathogens such as 
Candida albicans disseminate in the human body and cause damage to 
human tissues which could lead to dysfunction of the whole human body.  
Candida albicans is a leading fungal pathogen which causes death in 
humans. C. albicans possesses several virulence factors and has developed 
numerous mechanisms to evade the recognition and attack of the human 
body. Virulence factors can be secreted or surface-bound which C. albicans 
uses to start the infection process. During infection, the fungal pathogen uses 
several strategies to evade the attack of the human immune system either by 
making itself unrecognizable or degrading components of the human effector 
mechanisms. 
The current prevalence of C. albicans infections in humans and the high 
mortality rate caused by the fungal pathogen indicate that the pathogenesis is 
still not well understood. It was therefore the aim of this study to contribute to 
the understanding of the C. albicans-human host interplay with the hope that 
novel and effective ways could be discovered to inhibit the detrimental effects 
of C. albicans infection and improve quality of life. To achieve this, the work 
presented here investigated the roles of two surface proteins of C. albicans in 
the human tissue invasion and immune evasion. 
 
 
4.1. C. albicans phosphoglycerate mutase (Gpm1p) as a surface protein 
which mediates adhesion to human endothelial cells and keratinocytes 
using vitronectin as ligand 
 
Attachment of Candida albicans to human tissues greatly contributes to the 
virulence of the fungal pathogen in starting the infection process. Thus, it is 
important to know the mechanism by which C. albicans attaches to human 
cells prior to tissue invasion. It was therefore the aim of this work to describe 
the role of a specific surface protein on the direct contact of C. albicans with 
human cells, and identify the receptor on the surface of human cells which is 
responsible for the interaction.  
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In this study, the glycolytic enzyme Gpm1p, is identified to mediate the 
adhesion of the fungal pathogen C. albicans to the human cells. It was initially 
investigated if Gpm1p binds to human cells. Here, Gpm1p binds to endothelial 
cells and keratinocytes, but not to monocytes. This has a significant 
implication on the role of Gpm1p as a surface protein of C. albicans. It 
specifically identifies the protein as an adhesin for tissue adherence and not 
as a ligand for phagocytes which might lead to recognition and phagocytosis 
of the fungus. The role of Gpm1p in the binding of C. albicans to endothelial 
cells was confirmed by the decrease in the association (adherence 
and/endocytosis) of the GMP1 homozygous deletion strain to HUVEC.   
The lack of GPM1 decreases the ability of C. albicans to associate with 
human cells, but not totally abolishes it. This can be attributed to the fact that 
other surface proteins of C. albicans exist which can mediate the binding to 
endothelial cells such as Als3 [118,119] and Ssa1 [34,120,121]. To eliminate 
the effects of other surface proteins present on C. albicans, Gpm1p was 
coated on latex beads and association with endothelial cells was analyzed. 
Gpm1p mediated the association of the latex beads with the human 
endothelial cells. Thus, Gpm1p alone causes adhesion or/and endocytosis to 
and by endothelial cells which makes Gpm1p a relevant adhesin and/or 
invasin for endothelial cells. 
Candida Gpm1p binds to human keratinocytes. This is relevant since C. 
albicans is one of the leading pathogens to cause cutaneous infections. 
Gpm1p is identified as surface protein that adheres to skin cells which could 
lead to further invasion of the epidermal layers during skin infection. It is 
established that C. albicans binds to keratinocytes [68,119]. However, at 
present, no surface protein has been identified which directly mediates 
contact between C. alibicans and keratinocytes. Previous works have only 
identified mannose and phospholipomannan on the cell wall of C. albicans 
which triggers immune response by keratinocytes [120,121]. Thus, I identify 
Gpm1p as a new C. albicans surface protein which directly interacts with 
human keratinocytes.  
Screening for the possible ligand present on human cells led to the 
identification of the adhesive glycoprotein vitronectin. This work specifically 
identifies Gpm1p to be a vitronectin-binding protein of C. albicans.  It is further 
demonstrated in this study, through binding and blocking assays, that heparin-
binding sites (HBS) on the vitronectin molecule are involved in the interaction 
between Gpm1p and vitronectin. This is in line with the results of Limper et al 
(1994) which showed that C. albicans cells bind to the glycosaminoglycan-
binding region of vitronectin [68]. Interestingly, the same study identified a 30-
kDa surface protein of C. albicans which bound vitronectin through ligand 
blotting of radiolabelled vitronectin. The binding of the unknown C. albicans 
protein was also inhibited by heparin. Since Gpm1p is approximately 30-kDa 
in size and its binding to vitronectin is inhibited by heparin, there is a 
possibility that Limper et al were able to isolate Gpm1p in their study. Taken 
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together, Gpm1p is a surface protein of C. albicans which directly interacts 
with vitronectin by binding to its HBS. Binding of C. albicans to vitronectin can 
help the fungus to adhere to human tissues for colonization and subsequent 
invasion. This is the same molecular mechanism used by the bacterial 
pathogen Streptococcus pneumoniae in utilizing vitronectin to adhere to host 
cells and subsequent internalization. The pathogenic bacterium binds to the 
C-terminal HBS of vitronectin while the N-terminal integrin-binding site is free 
for interaction with human cells [101].  
This study identifies vitronectin on the surface of both HUVEC and HaCaT 
cells as the ligand for Gpm1p. Pre-incubation of additional vitronectin with 
Gpm1p does not promote binding of the fungal protein to human cells but 
inhibits it, instead. Interestingly, vitronectin is present on the surface of both 
HUVEC and HaCaT cells as shown by flow cytometry and LSM which 
explains the non-binding of the vitronectin-complexed Gpm1p. This is in line 
with a previous study which showed that addition of vitronectin to C. albicans 
yeast cells inhibited their binding to endothelial cells because of the already-
present vitronectin on the human cell surface [69]. The presence of vitronectin 
on the surface of endothelial cells, even after incubation in serum-free 
medium, was shown to be caused by the internalization and later deposition 
of the glycoprotein in the subendothelial matrix after exposure to vitronectin-
containing serum [122,123].  
Previous studies have shown that vitronectin interacts with C. albicans and 
that several vitronectin-binding proteins on the surface of the fungus exist, but 
none of them identified Gpm1p [67-69]. The reports showed that C. albicans 
has human integrin-like receptors which can bind vitronectin. These 
vitronectin-binding human integrin-like receptors on the surface of C. albicans 
were identified by flow cytometry using antibodies against the human integrins 
αvβ3 and αvβ5. The isolated C. albicans vitronectin receptors were described 
to range from 84-130 kDa in size using biochemical characterizations. 
However, in this study, the antibody against αvβ3 did not recognize the 30-kDa 
Gpm1p in ELISA (data not shown) which indicates that it is different from the 
ones identified by Santoni et al. and Spreghini et al. [69,70]. The Gpm1p-
vitronectin colocalization on the surface of endothelial cells and keratinocytes 
shown by LSM in this study further confirms that Gpm1p is a C. albicans 
surface protein which directly binds to the vitronectin on the surface of human 
cells. Taken together, Gpm1p is a surface protein of C. albicans which can aid 
the pathogenic fungus in human cell adhesion by binding to vitronectin. This is 
another mechanism by which C. albicans can interact with human endothelial 
and epithelial cells, in addition to the binding of C. albicans Als3 and Ssa1 to 
N-cadherin and E-cadherin for attachment, invasion and destruction of host 
tissues [34,118,124]. 
Gpm1p is one of the non-conventional surface proteins of C. albicans as it is 
known to be mainly present in the cytosol as an enzyme which is involved in 
glycolysis but has been shown to be present on the fungal surface by several 
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studies [37,72,125]. Other glycolytic enzymes also known to be present on the 
C. albicans cell surface are enolase (Eno1) and glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) [37,72,125,126].  Currently, not enough is known as 
to how these glycolytic enzymes become transported to the cell surface as 
they lack the signal sequence for secretion.  As surface proteins, Eno1 and 
Gapdh were described to bind the extracellular matrix proteins laminin and 
fibronectin, and plasminogen for tissue invasion [38,127]. Based on the 
results of this study, Gpm1p is the first non-conventional surface protein of C. 
albicans which is reported to bind to vitronectin.  
Vitronectin is not only found in the ECM but also in serum. In this study, C. 
albicans acquires vitronectin from serum through Gpm1p. Acquisition of 
vitronectin from serum by pathogenic bacteria such as Moraxella catarrhalis 
[98,99], Haemophilus influenza [94,95] has been shown to be an immune 
evasion strategy since vitronectin inhibits the formation of the terminal 
complement complex (TCC) which lyses foreign cells in the human body .  
However, since C. albicans is not lysed by the TCC due to its thick cell wall, 
the function of vitronectin acquisition from serum by the fungal pathogen with 
regard to immune evasion is under current investigation. 
 
 
4.2.  C. albicans translation elongation factor 1-alpha as multifunctional 
surface protein which interacts with the complement components and 
neutrophils 
 
Here, I show that translation elongation factor 1-alpha (Tef1p) of Candida 
albicans is a receptor for several complement components. Tef1p binds to the 
complement regulator Factor H, C4b-binding protein (C4BP), C3b degradation 
products C3d and C3dg, and plasminogen. The binding of Factor H by Tef1p 
was a confirmation of a previous study using protein array, affinity 
chromatography and mass spectrometry, identifying Tef1p as the fifth surface 
protein of C. albicans which bind Factor H. Among the other proteins identified 
are Gpm1p [61], Pra1 [62], Gpd2 [65] , and Hgt1p [63]. 
One of the mechanisms by which microbial pathogens evade the immune 
system is by binding complement system regulators, such as Factor H and 
C4BP, mainly to degrade the opsonin C3b and block opsonization. In the 
continuous discovery of C. albicans proteins that bind Factor H, Tef1p was 
identified in our laboratory as one of the Complement Regulator-Acquiring 
Surface Proteins (CRASPs) of C. albicans. This study confirms the binding of 
C. albicans Tef1p to human complement system regulators by producing 
recombinant Tef1p. The human complement system alternative pathway 
regulator Factor H and the classical pathway regulator C4b-binding protein 
(C4BP) bind to Tef1p, which is used by C. albicans to avoid being recognized 
by the human complement system. C. albicans binds Factor H, FHL-1 and 
C4BP as an immune evasion strategy [35,62]. However, it was only recently 
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that specific surface proteins were identified to be Factor H and C4BP 
receptors. Among these surface proteins are phosphoglycerate mutase 
(Gpm1p) [61], pH-regulated antigen 1 (Pra1) [62], glycerol-2-phosphate 
dehydrogenase (Gpd2) [65], and high-affinity glucose transporter (Hgt1p) [63]. 
Factor H and C4BP, when bound to the aforementioned proteins, maintain 
their C3b degradation activity as cofactor for Factor I. Other pathogenic fungi 
such as Aspergillus fumigatus have been also shown to bind complement 
regulators as a strategy to evade the immune system [60]. Aside from fungi, 
bacterial pathogens bind human complement regulators to evade the attack of 
the immune system and the proteins responsible for the binding have been 
identified. Some of them are PspC of Streptococcus pneumoniae, Scl1 of 
Streptococcus pyogenes, Sbi of Staphylococcus aureus, and YadA of 
Yersinia enterocolitica [83,129-133].  
C3b degradation products C3d and C3dg are identified in this study to be 
Tef1p ligands, which was confirmed by showing that TEF1 deletion mutant 
strain has decreased ability to bind C3d. However, the lack of TEF1 did not 
totally abolish the C3d binding capacity of the deletion strain. C. albicans 
possesses a C3d receptor on its surface and reports have described its 
expression, isolation and interaction with other proteins [48,49,115,134]. 
Previous studies were able to identify the surface C3d-binding protein by 
affinity chromatography and by its activity in inhibiting the rosetting of 
erythrocytes. The reports described the C3d receptor on C. albicans as a 
hyphae-expressed mannoprotein with a size of 62-72 kDa detected by the 
Complement Receptor 2 antibody. Thus, naming it as complement binding 
protein MP60 [48,135]. However, based on size alone, none of the studies 
identified the 50-52-kDa Tef1p. This indicates that Tef1p is a surface protein 
of C. albicans which binds the complement components C3d and C3dg. By 
binding the C3d or C3dg component of C3b, C. albicans inhibits the formation 
of C3 convertase, which subsequently inhibits C3b formation causing less 
opsonization of the fungus. C. albicans surface protein Pra1 employs this 
mechanism which was shown by Luo et al. (2011) [83]. There were also other 
speculations on the immune evasion functions of C3d binding by C. albicans. 
Some of them include the bridging of opsonized fungal cells and fungal cells 
with free binding sites for C3d, thereby producing cellular clumps which are 
hard to engulf by phagocytes; and shedding of the C3d receptor during 
infection to compete with complement receptors on phagocytes, which leads 
to non-detection of C. albicans [48]. In this study, the role of Tef1p binding of 
C3d has yet to be determined. 
I demonstrate in this study that Factor H dose-dependently binds to C3d-
bound Tef1p, forming a tripartite complex. The formation of tripartite complex 
consisting of a microbial protein, C3d and Factor H has been shown before for 
the S. aureus protein Sbi [83]. It was proven that Sbi-complexed C3d bound 
Factor H, which was active in inhibiting the complement cascade. It was 
therefore concluded that C3d assists in the direct binding of Factor H to Sbi. 
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Comparing to the results of this study, since Factor H can also bind to Tef1p 
alone, it can be speculated that binding of C3d/C3dg by Tef1p is an additional 
mechanism by which C. albicans can acquire more Factor H, which means 
stronger inhibition of the complement activation.  
Tef1p binding to plasminogen is demonstrated in this study. Here, it is shown 
that Tef1p bound to plasminogen in a dose-dependent manner and that the 
interaction involves lysine residues on the Tef1p molecule (Figure 14). In 
addition, deletion of TEF1 reduced the plasminogen binding ability of C. 
albicans but not totally abolish it (Figure 20A). This is consistent with the 
findings that C. albicans have several plasminogen binding proteins on its 
surface. As a plasminogen receptor on the surface of C. albicans, Tef1p was 
previously identified by Crowe et al. (2003) by using affinity chromatography 
[37,38]. Tef1p is one of several plasminogen binding surface proteins of C. 
albicans, together with catalase, thioredoxin peroxidase, phosphoglycerate 
mutase (Gpm1p), alcohol dehydrogenase (Adh1), glyceraldehyde-3-
phosphate dehydrogenase (Gapdh), phosphoglycerate kinase (Pgk1), 
fructose bisphosphate aldolase (Fba1), Pra1, Gpd2 and Eno1 
[37,38,61,62,65].  
Aside from the normal degradation activity of the natural substrates fibrinogen 
and vitronectin, the novel function of plasminogen binding by Tef1p is shown 
in this work to be the degradation of the C3b opsonin for immune evasion. 
Tef1p-bound plasminogen is accessible to the activator tPA which transforms 
plasminogen to the protease plasmin. The Tef1p-bound plasmin can then 
degrade the opsonin C3b into inactive fragments, thereby rendering C. 
albicans unrecognizable by phagocytes.  
Activation of the plasminogen bound on the surface of C. albicans leads to the 
degradation of the opsonin C3b, which leads to immune evasion by the fungal 
pathogen. It was indicated that the reason for binding of plasminogen by C. 
albicans is to degrade the extracellular matrix proteins on human tissues, 
which is the natural substrate of plasmin, to facilitate the invasion of the 
fungus. Eventhough it has been shown that plasmin-bound Candida cells can 
induce fibrinolysis and increase ability to cross an in vitro blood-brain barrier 
system, C. albicans can still destroy the endothelial matrix, and penetrate and 
damage endothelial cells in the absence of plasminogen [37]. The mechanism 
of plasminogen binding by C. albicans for C3b degradation is new from this 
study. Previous reports have shown that it is a common strategy used by 
bacteria to evade phagocytosis. Haemophilus influenza PE, Bacillus anthracis 
α-enolase and EF-tu, and S. aureus Sbi and Efb have all been shown to bind 
plasminogen, which when activated to the protease plasmin, degrades the 
opsonin C3b [5,84,110]. 
Tef1p localization in C. albicans cytoplasm and expression on the cell surface 
was investigated using the generated antiserum against Tef1p in Western 
blotting (Figure 17B). Tef1p expression on both the yeast and hyphal cells of 
C. albicans was also confirmed using flow cytometry (Figure 17C) and LSM 
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(Figure 17D). Tef1p presence on the surface of C. albicans was previously 
shown by Crowe et al. [37] and Urban et al. [79]. However, expression of 
Tef1p on hyphal cells is shown here to be stronger than on yeast cells. These 
results are in line with the gene expression studies done by Singh et al [136] 
and Zakikhany et al. [81] which showed that TEF1 gene is upregulated in 
pseudohyphae and hyphae forms during incubation with macrophages and 
epithelial cells. 
Deletion of TEF1 does not affect the growth of the fungus even in different 
environmental conditions. The previous speculation that TEF1 is an essential 
gene [87] has been disproven based on the results of this study. Here it is 
shown that even in the absence of TEF1, C. albicans can still grow like the 
wild type (Figure 19A and 19B). TEF1 deletion strain can also resist cell wall 
perturbing agents; and osmotic and oxidative stress. This implies that TEF1 is 
not essential in basic growth and metabolic functions of C. albicans. However, 
the protein Tef1p could still be essential since the protein is encoded by two 
genes, TEF1 and TEF2 [80]. Since only TEF1 gene was deleted in this study, 
the possibility that TEF2 encodes Tef1p and performs its essential role cannot 
be discounted. This is based on the fact that both TEF1 and TEF2 are 
translated equally and that C. albicans does not preferentially use one gene 
over the other [137]. This is also the case for the yeast Saccharomyces 
cerevisiae where deletion of TEF1 did not affect its growth. This was also 
attributed to the presence of TEF2 which encodes the same translation 
elongation factor EF-1α [138]. 
However, deletion of TEF1 makes C. albicans sensitive to the antibiotic 
hygromycin B (Figure 19F). Hygromycin B is an aminoglycoside that affects 
translational elongation by binding distinct sites at the ribosome in relative 
proximity to the ribosomal decoding center, thereby reducing translational 
fidelity [139]. The sensitivity of C. albicans TEF1 deletion strain to hygromycin 
B indicates that the encoded Tef1p plays a critical role in counteracting the 
effects of the antibiotic. This was demonstrated by De Backer [140] wherein 
overexpression of the Tef1p caused by depletion of mRNA 59-
guanylyltransferase gene (CGT1) in C. albicans led to the reduced sensitivity 
to hygromycin B. The result of this study is also in line with what was shown 
for S. cerevisiae wherein mutant forms of TEF2, which also encodes for the 
same protein as TEF1 [137] made the yeast sensitive to hygromycin B [141]. 
The possibility that C. albicans TEF2 could take over the production of Tef1p 
in the absence of TEF1 for counteracting the effects of hygromycin B cannot 
be ignored. But based on this work, The Tef1p produced by TEF2 alone is not 
sufficient to maintain translational fidelity in the presence of hygromycin B. 
Tef1p binding to neutrophils is demonstrated in this study. In addition to Pra1, 
Tef1p is identified as a C. albicans protein surface component which interacts 
with neutrophils. It is known that receptors on neutrophils recognize different 
components of the fungal pathogen’s surface. Dectin-1 recognizes the ß1-3 
glucan while Toll-like receptors collaborate with Dectin-1 in recognizing the 
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fungus using surface mannans. Another receptor on the surface of neutrophils 
is complement receptor 3 (CR3) which recognizes opsonized C. albicans cell. 
Opsonins C3d and iC3b opsonize the fungal pathogen and is recognized by 
CR2 and CR3, respectively. However, it has been shown that non-opsonized 
C. albicans cells are also recognized by neutrophils. It was discovered that 
Pra1 is directly recognized by CR3. However, since it is shown in this work 
that the lack of TEF1 decreases the ROS released by neutrophils, it suggests 
that Tef1p is specifically recognized by neutrophils and has a role in activating 
the myeloperoxidase-H2O2-halide system. The role of Tef1p in the production 
of ROS by neutrophils is highly speculative. It could be that Tef1p is 
recognized by neutrophils using another receptor since addition of antibodies 
against CD11b and CD18 (components of the integrin) did not block the 
binding of Tef1 to neutrophils (data not shown). But since there is a possibility 
that Tef1p is the C3d receptor with similarity to the CR3 sequence, it could be 
that the effect of the CR3 antibodies was counteracted. Taken together, the 
binding of C. albicans Tef1p could be an indication that the protein is 
recognized by the neutrophils and triggers a signaling cascade which induces 
the production of ROS. 
 
CONCLUSION 
 
In summary, this study characterizes two C. albicans surface proteins and 
their interaction with the human host. The proteins Gpm1p and Tef1p 
contribute to the adhesion to human tissue and evasion of the innate immune 
system, respectively. On one hand, Gpm1p binds vitronectin for adhesion to 
human tissues. It is described how Gpm1p specifically interacts with 
vitronectin and localize with the native vitronectin on the surface of both 
endothelial cells and keratinocytes. The C. albicans strain lacking the GPM1 
gene has decreased ability to be associated (adhered and/or endocytosed) 
with endothelial cells. On the other hand, Tef1p interacts with several 
components of the innate immune system for immune evasion. Tef1p binds 
the complement regulatory proteins Factor H and C4BP. Tef1p also binds the 
C3b fragments C3d and C3dg. A tripartite complex is shown to form between 
Tef1p, C3d and Factor H. In addition, Tef1p binding to plasminogen shows 
that the opsonin C3b can be degraded making it inactive for phagocyte 
recognition. Moreover, C. albicans Tef1p has a role in the interaction between 
the fungus and human neutrophils as evidenced by the inability of neutrophils 
to produce ROS when challenged with C. albicans lacking the TEF1 gene.  
It is interesting to note that both Gpm1p and Tef1p are non-canonical surface 
proteins of C. albicans due to the lack of secretion signal in their genetic 
sequences, which makes them moonlighting proteins. Knowledge of the 
mechanisms on how these proteins translocate to the surface of C. albicans is 
still nil and needs further investigation. 
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The findings of this study contribute to the further understanding on how C. 
albicans interacts with the human host using surface proteins. Application of 
the results presented here can be extended to clinical settings and discover 
how, for example, Gpm1p can be inhibited to bind to vitronectin on the 
surfaces of implants, such as catheters, in hospital patients. Another 
possibility is to find ways to disarm C. albicans in evading the immune attack 
by inhibiting the surface Tef1p. 
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THESIS STATEMENTS 
 
of the dissertation of Crisanto M. Lopez, M.Sc. 
 
 
The opportunistic fungus Candida albicans possesses virulence factors which 
are used to invade human tissues and evade the immune system. The ability 
to bind to human tissues for subsequent colonization and invasion, and to 
utilize human immune regulatory proteins for its own protection is achieved by 
C. albicans by expressing specific proteins on its cell surface. It was therefore 
the aim of this work to identify cell surface-associated proteins of C. albicans 
and elucidate the roles that they play in the virulence of the opportunistic 
fungus. The main findings of the study are: 
 
1. C. albicans uses its cell surface protein phosphoglycerate mutase 
(Gpm1p) to adhere to human umbilical vein endothelial cells (HUVEC) 
and keratinocytes (HaCaT). Deletion of the GPM1 gene which 
expresses Gpm1p decreases adherence of C. albicans to human cells. 
 
2. Gpm1p binds to vitronectin expressed by HUVEC and HaCaT. 
Recombinant Gpm1p colocalizes to the vitronectin expressed on the 
surface of HUVEC and HaCaT. Moreover, soluble vitronectin from 
human serum is bound by C. albicans through Gpm1p. 
 
3. Gpm1p interacts with vitronectin by binding to the heparin binding site 
on the vitronectin molecule.  
 
4. C. albicans expresses translation elongation factor 1-alpha (Tef1p) on 
the cell surface of both yeast and hyphal forms. 
  
5. C. albicans Tef1p binds complement regulatory proteins Factor H and 
C4BP; and C3 fragments C3b, C3d, C3dg and iC3b. Binding to these 
proteins could help C. albicans in the avoidance of being recognized by 
phagocytes.  
 
6. C. albicans Tef1p binds plasminogen which, when activated to plasmin 
by tissue-type plasminogen activator, maintains its degradation activity 
on synthetic substrate S-2251 and extracellular matrix proteins 
fibrinogen and vitronectin.  
 
7. C. albicans uses Tef1p to bind to plasminogen to degrade the opsonin 
C3b. Homozygous deletion of TEF1 (orf19.1435) decreases the 
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binding ability of C. albicans to plasminogen which could lead to less 
C3b degradation capability of C. albicans. 
 
8. When TEF1 of C. albicans is deleted, the mutant shows regular growth 
compared to the wildtype in normal fungal cultivation conditions. This 
could be accounted for the presence of the second C. albicans gene 
TEF2 (orf19.382) which encodes for an identical Tef1p.  
 
9. C. albicans TEF1 is dispensable for the resistance to osmotic and 
oxidative stresses, and cell wall perturbing agents. In contrast, TEF1 
deletion leads to increased sensitivity to hygromycin. 
 
10. C. albicans uses Tef1p to interact with neutrophils. Neutrophils produce 
less reactive oxygen species when TEF1 is lacking in C. albicans. 
 
11. Gpm1p and Tef1p are important virulence factors of C. albicans in the 
interaction with the human host. 
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THESEN 
zur Dissertation von Crisanto M. Lopez, M.Sc. 
 
Der opportunistische Pilz Candida albicans besitzt Virulenzfaktoren, die zur 
Invasion des menschlichen Gewebes und zur Evasion des Immunsystems 
verwendet werden. Die Fähigkeit an humane Gewebe zur nachfolgenden 
Kolonisierung und Invasion zu binden, sowie die Verwendung 
immunregulatorischer Proteine des Menschen zum Schutz der eigenen Zellen 
erreicht C. albicans durch die Expression spezieller Proteine auf seiner 
Oberfläche. Das Ziel der vorliegenden Dissertation war die Identifikation 
Zelloberflächen-assoziierter Proteine und der Aufklärung ihrer Rolle im 
Virulenz-regulatorischen Netzwerk von C. albicans. Die bedeutendsten 
Ergebnisse dieser Arbeit sind: 
 
1. C. albicans verwendet das Zelloberflächen-Protein 
Phosphoglyceratmutase (Gpm1p) um an Humane Umbilikalvene-
Endothelzellen (HUVEC) und Keratinozyten (HaCaT) zu binden. Die 
Deletion von GPM1, welches das für Gpm1p-kodierende Gen ist, führt 
zu einer Abnahme der Adhäsion von C. albicans an humane Zellen. 
2. Gpm1p bindet an Vitronectin, welches von HUVEC und HaCaT 
exprimiert wird. Rekombinantes Gpm1p ist in der Lage, mit dem von 
HUVEC und HaCaT exprimierten Vitronectin zu kolokalisieren. 
Weiterhin ist C. albicans durch Expression von Gpm1p in der Lage, in 
humanem Serum gelöstes Vitronectin zu komplexieren. 
3. Gpm1p interagiert mit Vitronectin und bindet es über die Heparin-
Bindestelle im Vitronectin-Molekül. 
4. C. albicans exprimiert den Translationselongationsfaktor 1-α (Tef1p) 
auf der Zelloberfläche sowohl von Hefezellen als auch auf Hyphen. 
5. Tef1p von C. albicans bindet die Komplement-regulatorischen Proteine 
Faktor H und C4BP, sowie C3 und dessen Fragmente C3b, C3d, C3dg 
und iC3b. Die Bindung an diese Faktoren kann C. albicans dabei 
helfen, die Erkennung durch Phagozyten zu verhindern.  
6. Plasminogen wird von C. albicans Tef1p gebunden und behält, nach 
dessen Aktivierung zu Plasmin durch den Gewebsspezifischen 
Plasminogenaktivator, seine Fähigkeit zur Degradation des 
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synthetischen Substrats S-2251 und den Extrazellulären 
Matrixproteinen Fibrinogen und Vitronectin bei. 
7. C. albicans verwendet Tef1p zur Bindung von Plasminogen, um das 
Opsonin C3b zu degradieren. Die homozygote Deletion von TEF1 
(orf19.1435) führt zu einer Abnahme der Bindefähigkeit von C. albicans 
an Plasminogen, was zu einer verringerten Fähigkeit der C3b-
Degradierung von C. albicans führen könnte. 
8. Nach einer Deletion von TEF1 in C. albicans zeigt die entsprechende 
Mutante ein zum Wildtyp vergleichbares Wachstum unter Standard-
Kulturbedingungen. Dies kann zurückzuführbar sein auf die 
Anwesenheit des Gens TEF2 (orf19.382), welches in C. albicans für 
die Expression eines identischen Tef1p kodiert. 
9. C. albicans tef1 trägt nicht bei zur Resistenz gegenüber osmotischem 
und oxidativem Stress, sowie gegenüber Zellwand-störenden Agenzien 
bei. Im Gegensatz führt die Deletion von TEF1 zu einer erhöhten 
Sensitivität gegenüber dem Antimykotikum Hygromycin. 
10. C. albicans verwendet Tef1p um mit Neutrophilen zu interagieren. 
Diese zeigen eine geringere Bildung von Reaktiven Sauerstoffspezies 
wenn Tef1p in C. albicans fehlt. 
11. Die gezeigten Ergebnisse lassen den Schluss zu, dass die Proteine 
Gpm1p und Tef1p von C. albicans wichtige Virulenzfaktoren für die 
Interaktion mit den Menschen als Wirt darstellen. 
 
